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Dehydroepiandrosterone (DHEA) is an androgenic steroid predominantly viewed as the main 
precursor to androgen and estrogen hormones in the human body. DHEA exists as a sulphated 
ester known as DHEAS, which is also the most predominant steroid hormone in human circulation. 
A decline in circulating DHEA concentrations is associated with age, inflammatory disease, as well 
as neurodegenerative pathologies. It has numerous demonstrated neuroprotective, anti-
inflammatory and anti-glucocorticoid effects. The human adrenal glands and gonads are the main 
sites for DHEA biosynthesis in the periphery, but historical evidence has suggested that central 
steroid biosynthesis, termed neurosteroidogenesis, is responsible for the presence of DHEA in the 
brain. The process of neurosteroidogenesis has to date proven to be an elusive process, as only 
a handful of relatively dated studies have provided evidence for its existence. Furthermore, clear 
differences are apparent in systemic rodent steroidogenesis and human steroidogenesis, the latter 
of which most the evidence of neurosteroidogenesis is formulated upon. In order to exploit the 
numerous reported beneficial effects of DHEA in the brain, it is pertinent that we understand how 
it is synthesised, how it may exert its effects centrally and whether species differences will affect 
the function thereof. 
Utilising the sensitivity and specificity of Ultra-Performance Convergence Chromatography 
(UPC2)-tandem mass spectrometry we comprehensively assessed the ability of primary human 
astrocytes (pHAs) and primary rat brain ex vivo mixed cell cultures (pRBMCs) to synthesise DHEA 
from a known substrate, pregnenolone, in the presence or absence of steroidogenic modulators. 
Additionally, we also sought to elucidate the ability of the cells to metabolise DHEA, in either the 
presence or absence of steroidogenic modulators. 
Both pHAs and pRBMCs were unable to synthesise DHEA from pregnenolone as the substrate in 
the absence or presence of steroidogenic modulators. pHAs and pRBMCs were able to convert 
pregnenolone in progesterone, demonstrating 3β-HSD activity. Additionally, although both cell 
populations were unable to demonstrate DHEA biosynthesis, they were able to convert exogenous 
DHEA into androstenedione and androstenediol, demonstrating not only 3β-HSD, but17β-HSD 
activity as well. This is the first study demonstrating androstendiol biosynthesis by human glial 
cells. 
The inability of pHAs and pRBMCs to synthesise DHEA from pregnenolone as a substrate 
contradicts available literature. The metabolism of exogenous DHEA into downstream metabolites 
suggests that the numerous beneficial effects of DHEA are not due to the steroids itself, but rather 
its metabolites. This current characterisation of DHEA metabolism both questions our current 
understanding of DHEA biosynthesis in the brain and holds promise for new therapeutic 





Dehydroepiandrosterone (DHEA) is ‘n androgeniese steroïedhormoon wat hoofsaaklik as die 
belangrikste voorloper vir androgeen en estrogeen hormone in die menslike liggaam beskou word. 
DHEA bestaan ook as 'n gesulfateerde ester, bekend as DHEAS, wat ook die volopste 
steroïedhormoon in die menslike bloedsomloop is. 'n Afname in die sirkulerende DHEA 
konsentrasies word geassosieer met ouderdom, inflammatoriese siektes, sowel as 
neurodegeneratiewe patologieë. Dit het talle neurobeskermende, anti-inflammatoriese en anti-
glukokortikoïede effekte. Die menslike byniere en gonades is die belangrikste organe vir DHEA-
biosintese in die periferie, maar historiese bewyse dui aan dat sentrale steroïedbiosintese, wat 
neurosteroïedgenese genoem word, verantwoordelik is vir die teenwoordigheid van DHEA in die 
brein is. Die proses van neurosteroïedgenese is tot dusver 'n ontwykende proses, aangesien slegs 
'n handjievol relatief verouderde studies bewys lewer dat dit bestaan. Verder is daar duidelike 
verskille in sistemiese knaagdiersteroïedgenese en menslike steroïedgenese, waarvan 
laasgenoemde die bewys van neurosteroïedgenese is. Om die talle gerapporteerde voordelige 
gevolge van DHEA in die brein te benut, is dit pertinent dat ons verstaan hoe dit gesintetiseer word, 
hoe DHEA sy effekte sentraal kan uitoefen en of spesieverskille die funksie daarvan sal beïnvloed. 
Deur gebruik te maak van die sensitiwiteit en spesifisiteit van ultra werkverrigting konvergensie-
chromatografie (UPC2)-tandem-massaspektrometrie, het ons die vermoë van primêre menslike 
astrosiete (pHA's) en primêre rotbrein ex vivo gemengde selkulture (pRBMC's) om DHEA vanaf 
die bekende substraat pregnenoloon te sintetiseer, in die teenwoordigheid of afwesigheid van 
moduleerders van steroïedgenese. Daarbenewens het ons ook probeer om die vermoë van hierdie 
selle om DHEA te metaboliseer, onder dieselfde toestande, toe te lig. 
Beide pHA's en pRBMC's kon nie DHEA van pregnenoloon as substraat sintetiseer nie. Die 
afwesigheid of teenwoordigheid van moduleerders van steroïedgenese het ook nie hierdie 
bevinding beïnvloed nie. pHA's en pRBMC's het 3β-HSD-aktiwiteit getoon deur pregnenoloon na 
progesteroon om te skakel. Alhoewel beide selpreparate nie DHEA-biosintese kon demonstreer 
nie, kon hulle wel eksogene DHEA in androsteendioon en androsteendiol omskakel, wat nie net 
3β -HSD, maar ook 17β-HSD aktiwiteit demonstreer. Dit is die eerste studie wat die biosintese van 
androsteendiol deur menslike glanselle demonstreer. 
Die onvermoë van pHA's en pRBMC's om DHEA vanaf pregnenoloon as substraat te sintetiseer 
stem nie ooreen met die beskikbare literatuur nie. Die metabolisme van eksogene DHEA na 
stroom-af metaboliete dui daarop dat die talle voordelige effekte van DHEA nie te wyte is aan dié 
steroïed spesifiek nie, maar eerder die metaboliete daarvan. Hierdie huidige karakterisering van 
DHEA-metabolisme bevraagteken ons huidige begrip van DHEA-biosintese in die brein, maar hou 





Firstly, I would like to acknowledge and thank the following funding bodies for financial support 
over the past three years: 
• The National Research Foundation
• The Ernst and Ethel Eriksen Trust
• The Stellenbosch University Postgraduate Funding Office
Secondly, I would like to thank my supervisors, colleagues, friends and family. 
To Prof Carine Smith, thank you for taking a chance on me, for the constant motivation and 
for the consistent support. I hope that one day I can be half the person and academic you are. 
Thank you for setting the bar. 
To Prof Amanda Swart, Dr Therina du Toit and Ms Des van Rooyen for the unending guidance 
and help through the complex world of steroidogenesis. Thank you most of all for your 
patience. 
To the Stellenbosch University International Services Team. Thank you for your support and 
patience over the past two years. I can honestly say that my life has become richer from 
knowing and working with you. 
I would like to thank all of my friends (in no particular order); Kelly Petersen, Tracey Ollewagen, 
Rohan Benecke, Danielle Millar, Sulandy Reuter and Hanna Kotze. Thank you for being my 
sounding boards (even though some of you had no idea what I was talking about most of the 
time). Thank you for keeping me sane in dark times and always lending an ear to my neurotic 
ramblings.  
To my sister and my dad, thank you for your constant love, support and sacrifice. It never went 
unnoticed. 
To my mom, thank you for believing in me when I couldn’t believe in myself. I will probably 
never be able to repay you for all of your sacrifice, but I hope this can be a small drop in the 
ocean you deserve. This is for you. 




List of figures ........................................................................................................................ 3 
List of tables .......................................................................................................................... 5 
List of abbreviations .............................................................................................................. 6 
Chapter 1 ............................................................................................................................ 11 
1.1. Introduction ....................................................................................................... 11 
Chapter 2 ............................................................................................................................ 14 
2. Literature Review ..................................................................................................... 14 
2.1. Introduction ....................................................................................................... 14 
2.2. Process of ageing .............................................................................................. 16 
2.3. Immune system maladaptation .......................................................................... 17 
2.4. Endocrine Dysfunction ....................................................................................... 19 
2.5. DHEA – the magic bullet? ................................................................................. 23 
2.6. Direct and indirect evidence for neuroprotective anti-inflammatory effects of DHEA
  .......................................................................................................................... 25 
2.7. Potential mechanisms for DHEA-mediated neuroprotective effects ................... 27 
2.8. Efficacy of therapeutic DHEA administration ..................................................... 31 
2.9. Is it possible to stimulate extragonadal biosynthesis of DHEA or DHEAS? ........ 32 
2.10. DHEA Biosynthesis ........................................................................................... 33 
2.11. Production sites of DHEA .................................................................................. 34 
2.12. Practical challenges in steroidogenesis research .............................................. 40 
2.13. Conclusions ....................................................................................................... 43 
2.14. Problem Statement ............................................................................................ 43 
2.15. Hypothesis ........................................................................................................ 43 
2.16. Aims .................................................................................................................. 43 
2.17. Objectives ......................................................................................................... 43 
Chapter 3 ............................................................................................................................ 44 
3. Materials and Methods ............................................................................................. 44 
3.1. Materials............................................................................................................ 44 
Stellenbosch University https://scholar.sun.ac.za
2 
3.2. Methods ............................................................................................................ 45 
Chapter 4 ............................................................................................................................ 54 
4. Results ..................................................................................................................... 54 
4.1. Steroidogenesis characterisation of primary human astrocytes ......................... 54 
4.2. Light microscopy morphological characterisation of primary rat brain ex vivo mixed 
cell culture .................................................................................................................... 59 
4.3. Confocal analysis of primary rat brain ex vivo mixed cell culture confirmed the 
presence of astrocytes and microglia ........................................................................... 60 
4.4. Steroidogenesis characterisation of primary rat brain ex vivo mixed cell cultures .. 
  .......................................................................................................................... 62 
4.5. Comparison of synthesised analyte concentrations between pHAs and pRBMCs 
(species differences) .................................................................................................... 67 
4.6. Deconjugation assay ......................................................................................... 68 
4.7. Detectable steroids in sulphatase enzyme treated pHA and pRBMC samples .. 70 
Chapter 5 ............................................................................................................................ 77 
5. Discussion ................................................................................................................ 77 
5.1. Main findings ..................................................................................................... 77 
5.2. DHEA ................................................................................................................ 82 
5.3. Androstenediol (A5) ........................................................................................... 85 
5.4. Summary of findings .......................................................................................... 87 
Chapter 6 ............................................................................................................................ 88 
6. Conclusion ............................................................................................................... 88 





List of figures 
Figure 2-1: Representative diagram of reported steroidogenic enzyme expression reported in 
different brain cell types. ..................................................................................................... 35 
Figure 2-2: The process of steroidogenesis in rodents and humans. ................................... 41 
Figure 4-1: Detectable steroids produced by pHAs in experimental conditions containing P5 
as a substrate with or without steroidogenic modulators ..................................................... 55 
Figure 4-2 Detectable steroids produced by pHAs in experimental conditions containing DHEA 
as a substrate with or without steroidogenic modulators. .................................................... 56 
Figure 4-3: Comparison between initial P5 concentration and recovered concentration after 
treatment of pHAs. .............................................................................................................. 57 
Figure 4-4: Comparison between initial DHEA concentration and recovered concentration after 
treatment of pHAs (A); A5 concentrations in different conditions (B). .................................. 58 
Figure 4-5: Light micrograph of primary rat brain ex vivo mixed cell culture after 7 days of 
culture. ................................................................................................................................ 59 
Figure 4-6: Confocal analysis of primary rat brain ex vivo mixed cell culture. ...................... 61 
Figure 4-7: Detectable steroids produced by pRBMCs in experimental conditions containing 
P5 as a substrate with or without steroidogenic modulators. ............................................... 63 
Figure 4-8 Detectable steroids produced by pRBMCs in experimental conditions containing 
DHEA as a substrate with or without steroidogenic modulators. .......................................... 64 
Figure 4-9: Comparison between initial P5 concentration and recovered concentration after 
treatment of pRBMCs. ......................................................................................................... 65 
Figure 4-10: Comparison between initial DHEA concentration and recovered concentration 
after treatment of pHAs (A); A4 concentrations in different conditions (B).. ......................... 66 
Figure 4-11: Comparison between pHA and pRBMC synthesised A5 concentrations of 
different treatment groups.. ................................................................................................. 67 
Figure 4-12: Efficiency of sulphatase (A) and glucoronidase (B) enzymatic activity. ............ 68 
Figure 4-13: Biosynthesis of A4 in STS treated DHEA and DHEAS positive controls. ......... 69 
Figure 4-14: Comparison between P5 (A) and P4 (B) concentrations of samples from pHAs 
before and after treatment with STS in different treatment groups....................................... 71 
Figure 4-15: Comparison between DHEA (A), A4 (B) and A5 (C) concentrations of samples 
from pHAs before and after treatment with STS in different treatment groups. .................... 73 
Figure 4-16: Comparison between P4 (A) and P4 (B) concentrations of samples from pRBMCs 
before and after treatment with STS in different treatment groups....................................... 74 
Figure 4-17: Comparison between DHEA (A), A4 (B) and A5 (C) concentrations of samples 
from pRBMCs before and after treatment with STS in different treatment groups ............... 76 
Figure 5-1: The steroidogenesis pathway revisited ............................................................. 78 
Stellenbosch University https://scholar.sun.ac.za
4 
Figure 5-2:The “hybrid” steroidogenesis pathway. ............................................................... 81 
Figure 5-3: Summary of metabolism of pregnenolone (P5) and dehydroepiandrosterone 






List of tables 
Table 2-1: Summary of reports linking DHEA to neurodegenerative diseases and 
neurocognitive disorders ..................................................................................................... 16 
Table 2-2:  Evidence for beneficial effects of administered DHEA/DHEAS or metabolites 
reported in pre-clinical studies ............................................................................................. 24 
Table 2-3: Studies which have demonstrated anti-inflammatory effects of DHEA or DHEAS 
outside of the CNS .............................................................................................................. 26 
Table 2-4: Illustrating the variety of studies reporting favourable effects of DHEA/DHEAS 
supplementation in clinical pathologies ............................................................................... 31 
Table 3-1: Different experimental groups containing different stimulants and inhibitors of 
steroidogenesis ................................................................................................................... 48 
Table 3-2: Master mix of deuterated internal standards. Each 50 µL of the master mix 
contained the amount of respective standard below (ng): ................................................... 48 
Table 3-3: List of steroid standards with retention times (RT); molecular ion species and MRM 
mass transitions; and reference internal standards ............................................................. 51 
Table 3-4: Limits of Detection (LOD) and Limits of Quantifications (LOQ) for different steroid 






List of abbreviations 
µg      Microgram 
µL      Microlitre 
µM      Micromolar 
16OHP4     16α-hydroxyprogesterone 
16OHP5     16α-hydroxypregnenolone 
17OHP4     17α-hydroxyprogesterone 
17OHP5     17α-hydroxypregnenolone 
3-NP      3-Nitropropionic acid 
3αAdiol     Androstanediol 
5αdione     Androstanedione 
A4      Androstenedione 
A4S      Androstenedione Sulphate 
A5      Androstenediol 
AD      Alzheimer’s disease 
ALLO      epi-Allopregnanolone 
AR      Androgen Receptor 
AST      Androsterone 
BBB      Blood Brain Barrier 
BDNF      Brain Derived Neurotrophic Factor 
CD11b      complement receptor 3 
CNS      Central Nervous System 
CS      Corpus Striatum 
CSF      Cerebral Spinal Fluid 
CYP2D     Cytochrome P450 2D 
DHEA      Dehydroepiandrosterone 
Stellenbosch University https://scholar.sun.ac.za
7 
DHEAS     Dehydroepiandrosterone Sulphate 
DHP4      Dihydroprogesterone 
DHT      Dihydrotestosterone 
DMEM      Dulbecco’s Modified Eagle’s medium 
E. coli      Escherichia coli 
EAE      Experimental autoimmune encephalomyelitis 
ER      Estrogen Receptor 
ERK ½      Extracellular signal-regulated kinases -1/2 
EtOH      Ethanol 
FBS      Foetal Bovine Serum 
FIV      Feline Immunodeficiency Virus 
GABAA R     GABAA Receptor 
GABAA     γ-aminobutyric acid type A 
GCMS      Gas Chromatography 
GC-MS     Gas Chromatography Mass Spectrometry 
GFAP      Glial Fibrillary Acidic Protein 
GR      Glucocorticoid Receptor 
H. pomatia     Helix pomatia 
hCG      human chorionic gonadotropin 
HPA      Hypothalamic Pituitary Adrenal axis 
HPLC      High Performance Liquid Chromatography 
HSD      Hydroxysteroid Dehydrogenase 
IFN-γ      Interferon gamma 
IL      Interleukin 
LCMS      Liquid Chromatography Mass Spectrometry 
LH      Luteinising Hormone 
Stellenbosch University https://scholar.sun.ac.za
8 
LPS      Lipopolysaccharide 
LTP      Long Term Potentiation 
MAP2C     Microtubule Associated Protein isoform 2C 
MCP-1      Monocyte Chemoattractant Protein 1 
MeOH      Methanol 
mg      Milligram 
MHC II      Major Histocompatibility Complex II 
mL      Millilitre 
mM      Millimolar 
MOA      Monoamine Oxidase 
MR      Mineralocorticoid Receptor 
mRNA      Messenger Ribonucleic Acid 
MS      Multiple Sclerosis 
MSMS      Tandem Mass Spectrometry 
MTBE      Methyl-tert-Butyl-Ether 
NAc      nucleus accumbens 
NF-κB nuclear factor kappa-light-chain-enhancer of 
activated B cells 
ng      Nanogram 
NGF      Nerve Growth Factor 
nL      Nanolitre 
nM      Nanomolar 
NMDA      N-methyl-D-aspartate 
NMDAR     NMDA Receptor 
NT-3      Neurotrophin 3 
OATP      Organic Anion Transporting Peptide 
Stellenbosch University https://scholar.sun.ac.za
9 
P4      Progesterone 
P450      Cytochrome P450 enzyme 
P450scc     Cytochrome P450 side chain cleavage enzyme 
P4S      Progesterone Sulphate 
P5      Pregnenolone 
P5S      Pregnenolone Sulphate 
PBMC      Peripheral Blood Mononuclear Cell 
PD      Parkinson’s disease 
PenStrep     Penicillin-Streptomycin 
PI3/Akt Phosphatidylinositol-4,5-bisphosphate 3-kinase/ 
Protein Kinase B 
PPAR      Peroxisome Proliferator-Activated Receptor 
PTSD      Post Traumatic Stress Disorder 
RIA      Radioimmunoassay 
ROS      Reactive Oxygen Species 
RPM      Revolutions per minute 
SAM      Sympatho-adrenal-medullary 
SFC      Supercritical Fluid Chromatography 
Shc      SHC-transforming protein 
SNS      Sympathetic Nervous System 
SPE      Solid Phase Extraction 
StAR      Steroidogenic Acute Regulatory Protein 
STS      Steroid Sulphatases 
SULT      Steroid sulphotransferase 
T      Testosterone 
TNF      Tumour Necrosis Factor 
Stellenbosch University https://scholar.sun.ac.za
10 
Trk      Tropomyosin receptor kinase 
UPC2 Ultra-Performance  Convergence 
Chromatography 






Dehydroepiandrosterone (DHEA) is an androgen steroid hormone that is largely viewed as a 
precursor to androgens and estrogens, in men and women respectively. It exists as a 
sulphated ester, dehydroepiandrosterone sulphate (DHEAS), which is the most abundant 
steroid hormone in human circulation. Although lacking a specific receptor and long thought 
to exist solely as a precursor hormone, DHEA has been shown to have numerous beneficial 
effects in its own right, within various contexts. These include neuroprotective, antioxidant and 
anti-inflammatory capacity (Grimm et al., 2014; Yabuki et al., 2015; Alexaki et al., 2017; 
Boghozian et al., 2017; Powrie and Smith, 2018). 
Traditionally, the biosynthesis of steroid hormones, termed steroidogenesis, was thought to 
occur only in the gonads and adrenal glands. However, in 1981, Corpéchot and colleagues 
published data demonstrating the presence of DHEA and DHEAS in the brains of adult male 
and female Sprague-Dawley rats (Corpéchot et al., 1981). To discount the possibility of 
systemic delivery, the animals underwent gonadectomies and adrenalectomies, but DHEAS 
levels remained unchanged. Systemic administration of dexamethasone or corticotropin 
similarly had no effect on DHEAS concentrations in the brain. The authors coined the term 
neurosteroid to differentiate the origins of steroids from the central nervous system versus the 
somatic endocrine system. In further studies of rat brains by the same authors, the presence 
of pregnenolone (P5) and its sulphated form, pregnenolone sulphate (P5S) was also reported 
(Corpéchot et al., 1983; Robel and Baulieu, 1985; Robel et al., 1987). Less than a decade 
later, a study by a different group reported the presence of other steroid hormones, in addition 
to DHEA, in the human brain – these included  progesterone (P4), androstenedione (A4) and 
17-hydroxyprogesterone (17OHP4) (Lacroix et al., 1987).  
Although these studies demonstrated the presence of steroids in rat and human brain as well 
as evidence suggesting central biosynthesis, neurosteroidogenesis remained unproven at this 
point. The first study directly demonstrating neurosteroidogenesis was conducted in isolated 
mitochondria from rat oligodendrocytes: these cells were shown to be able to convert 
cholesterol into P5 – the initial and rate limiting step in steroidogenesis (Hu et al., 1987). In 
years to follow, multiple studies reported data demonstrating the ability of isolated rat 
neuroglia, namely oligodendrocytes and astrocytes, to synthesise neurosteroids when 
provided with the relevant substrate (Jung-Testas et al., 1989b, 1989c; Zwain et al., 1997; 
Zwain and Yen, 1999a, 1999b; Gago et al., 2001).  
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In addition to data supporting the existence of neurosteroidogenesis, expression of multiple 
steroid enzymes in the rat brain has also been reported by a multitude of independent 
laboratories (Martel et al., 1992; Melcangi et al., 1993; Mellon and Deschepper, 1993; Dupont 
et al., 1994; Normand et al., 1995; Pelletier et al., 1995; Strömstedt and Waterman, 1995; 
Guennoun et al., 1995; Zwain et al., 1997; Kohchi et al., 1998; Ukena et al., 1998, 1999; Zwain 
and Yen, 1999a, 1999b; Gago et al., 2001; Kimoto et al., 2001; Benmessahel et al., 2002, 
2004; Sanne and Krueger, 2002; Lovelace et al., 2003; Shibuya et al., 2003; Sierra et al., 
2003; Griffin et al., 2004; Lavaque et al., 2006; Mukai et al., 2006; Geerling et al., 2006; Karri 
et al., 2007; Gottfried-Blackmore et al., 2008; Mizoguchi et al., 2014). Most relevant amongst 
these is cytochrome P450 c17 (CYP17), which is responsible for conversion of P5 into 17-
hydroxypregnenolone (17OHP5) as well as 17OHP5 into DHEA.  
Although evidence supporting neurosteroidogenesis in rodent brains appears insurmountable, 
the data available to support the process in human brains remains limited, if not inconsistent. 
Only two studies have reported detectable levels of steroid enzyme mRNA, including CYP17, 
in the human brain (Yu et al., 2002; Brown et al., 2003). Specific parts of the brain shown to 
express the mRNA were the amygdala, caudate nucleus, cerebellum, corpus callosum, spinal 
cord, thalamus and frontal cortex. Interestingly, the first study detected CYP17 mRNA in the 
hippocampus whilst the second did not (Brown et al., 2003). At least one other study has also 
reported failure to detect CYP17 mRNA in the hippocampus (MacKenzie et al., 2008). 
Furthermore,  contradicting data from others  demonstrate that the human temporal lobe and 
cerebellum also do not express CYP17 mRNA (Steckelbroeck et al., 2004; MacKenzie et al., 
2008). 
Despite the inconsistencies in the available data on neurosteroidogenesis in the human brain, 
as previously mentioned, animal studies have suggested that the process appears to 
preferentially occur in neuroglial cells. In particular, astrocytes – which express CYP17 and 
are theoretically capable of synthesising DHEA from P5 – seems to be the commonly accepted 
primary site of DHEA biosynthesis in the rodent brain (Zwain and Yen, 1999a). 
In terms of human models, we could find only one group who has investigated the ability of 
human astrocytes as well as human glioma cell lines to synthesise DHEA (Brown et al., 2000). 
They reported that normal human astrocytes (as well as the glioma cells)  expressed CYP17, 
but appeared to synthesise DHEA in a manner independent of the steroid pathway, which they 
theorised to be a ROS (Reactive Oxygen Species)-dependent pathway (Brown et al., 2000). 
However, no new data have been published to shed light on this theory for almost 20 years, 
despite the recent focus on redox in the context of neurodegenerative disease. Also, given the 
methodological limitations at the time these studies were conducted (Powrie and Smith, 2018), 
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conclusive interpretation from these few studies in only one group is probably premature. 
Thus, at this point, human astrocytes have not conclusively been shown to directly synthesise 
DHEA de novo or in the presence of a substrate. However, given the many beneficial 
associations more recently reported for DHEA in the context of oxidative stress, ageing and 
neuroinflammation, the possibility of intracrine DHEA biosynthesis – and potential therapeutic 
manipulation thereof – warrants further research.   
Since many species differences have already been reported for androgen steroidogenesis, as 
recently reviewed (Powrie and Smith, 2018), an important first step in this research approach 
would be to establish similarities or differences between species in the context of intracrine 
DHEA production. The current study therefore aimed to comprehensively investigate the 
ability of primary human astrocytes to produce and/or metabolise DHEA in vitro in response 
to different stimuli. 
The layout of the dissertation is as follows: Chapter 2 reviews the pertinent literature on the 
role of DHEA in modern chronic disease with particular focus on neurodegenerative 
pathologies. In addition, the potential of central DHEA biosynthesis is discussed in detail with 
special focus on species differences in steroidogenesis. This chapter concludes with the 
hypothesis, aims and objectives for the study. Chapter 3 details the materials used and 
methods employed to satisfy the aims of the study. Chapter 4 is a discussion of the results in 






2. Literature Review 
A truncated version of this chapter has been published in the Journal of Neuroinflammation 
(impact factor 5.7). 
Citation reference: Powrie, YSL. and Smith, C. Central intracrine DHEA biosynthesis in 
ageing-related neuroinflammation and neurodegeneration: therapeutic potential?. Journal of 
Neuroinflammation. 2018 15(1): 289 (https://doi.org/10.1186/s12974-018-1324-0) 
2.1. Introduction 
From the recent literature, it is evident that the processes of neuroinflammation and 
neurodegeneration are inextricably linked. Given the sequestered nature of the brain, which 
complicates research sample collection for obvious reasons, many investigators seem to 
extrapolate data generated from peripheral samples in attempts to explain central events. 
However, as also illustrated in the pages to follow, there is often a disconnect between 
adaptation in the periphery versus those occurring centrally. In our opinion, there are multiple 
reasons for this. Firstly, the neuroimmune system is structurally distinct from the peripheral 
system in that most immune functions are mediated by cells specific to the nervous system, 
such as microglia and astrocytes (Tian et al., 2012). Incidentally, although recent 
commentaries and research letters pertaining to the identification of a lymphatic system in the 
dural spaces are suggesting that the brain may be subject to surveillance by immune cells 
circulating from the periphery (Louveau et al., 2015), not enough data exist with which to 
evaluate the relative importance of these immune cells relative to those resident in the brain. 
Secondly, the brain has a preference for glucose as a substrate, as opposed to most 
peripheral organs, such as the heart, which mainly derive energy through fatty acid β-
oxidation, which may affect the outcome of adaptive – or maladaptive - metabolic responses 
differently in the brain to peripheral compartments. Lastly, although the brain itself is subject 
to glucocorticoid-mediated metabolic modulation, as in the peripheral compartment, it is also 
directly affected by – and thus adapts as result of - psychological input.  
From this, it is clear that different factors come into play centrally vs. peripherally in terms of 
adaptation to stimuli. This questions the validity of treating neuroinflammation – especially in 
the context of chronic disease aetiology – using the same strategies by which peripheral 
chronic low-grade inflammation is addressed. It further highlights the need for specific, central 
investigations for the purpose of answering questions pertaining to central physiological 
adaptation or maladaptation. 
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We have identified the hormone (also aptly referred to as a neurosteroid) 
dehydroepiandrosterone (DHEA) as a relatively under-researched hormone in the context of 
neurophysiology, despite its very clear association with a plethora of clinical disease states. 
DHEA, which is predominantly synthesized in the human adrenal cortex, also exists as a 
sulphated ester known as DHEAS, which is formed when DHEA is processed by the enzyme 
steroid sulphotransferase (SULT) (Maninger et al., 2009; Arbo et al., 2016). Of note, the 
majority of DHEA in circulation exists as DHEAS due to it having a stronger binding affinity for 
its carrier protein, albumin (Puche and Nes, 1962). DHEA is the precursor hormone to both 
androgenic and estrogenic hormones and as such, is also synthesised to a smaller extent in 
human gonads. In addition, and most relevant to the context of the current topic, it is claimed 
to be synthesised de novo in the human brain as well. In fact, DHEA concentrations in the 
human brain have been shown to be higher than that in circulation, while DHEAS 
concentrations are lower (Stárka et al., 2015; Arbo et al., 2016), which not only supports the 
theory of local biosynthesis, but also testifies to the importance of this hormone centrally.  
In the context of human health, DHEA has historically been deemed to have limited 
importance, until low circulating levels of DHEAS were associated with chronic and age-
related diseases such as diabetes, hypertension, arthritis, etc. (Barrett-Connor, 1992; Haffner 
et al., 1994; Herbert, 1995; Straub et al., 1998; Ravaglia et al., 2002). In addition, it has since 
drawn much media attention as being an “anti-ageing” supplement after circulating levels were 
also reported to dramatically and progressively decline with age (Orentreich et al., 1984; 
Herbert, 1995). Most relevant to the current context, abnormal changes in DHEA levels in 
serum and cerebral spinal fluid (CSF) have also been reported in the pathophysiology of 
neurodegenerative diseases such as Alzheimer’s disease (AD), schizophrenia and multiple 
sclerosis (MS), as well as neurocognitive pathologies such as post-traumatic stress disorder 
(PTSD) (a summary of these reports is provided in Table 2-1). However, much remains 
unknown about DHEA’s mode of action in the human body, or the reason for its age-related 
decline. Therefore, and given the commonly accepted phenomenon of accelerated ageing in 
many chronic disease states (Petersen and Smith, 2016), understanding the process of ageing 
and the physiological role of DHEA in this process, may be of benefit to the development of 
novel strategies in the treatment of these enigmatic pathologies.  
With this review, we provide a comprehensive summary of what is known about the role of 
DHEA in the context of neurophysiology and ageing. This will be followed by a discussion of 
specific topical issues, such as the effect of sex and species, as well as the sites for DHEA 
production. More specifically, relevant literature providing arguments for and against central, 
intracrine DHEA production is discussed in order to make an interpretation on the likelihood 
of central DHEA biosynthesis taking place, as well as on the feasibility of modulating central 
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DHEA levels for therapeutic effect in the context of ageing-related neuroinflammation and -
degeneration. 
Table 2-1: Summary of reports linking DHEA to neurodegenerative diseases and neurocognitive 
disorders   
 
Disease Findings References 
Alzheimer’s disease Significant decrease in serum DHEA and DHEAS levels when 
compared to aged-matched control patients 
(Sunderland et al., 1989; 
Yanase et al., 1996; 
Bernardi et al., 2000; 
Hillen et al., 2000; 
Murialdo et al., 2001; 
Genedani et al., 2004; 
Aldred and Mecocci, 
2010) 
Schizophrenia Data on both sides of the spectrum associate both abnormally 
elevated and declining levels of DHEA/DHEAS with the disease. 
This opposing data could be related to the heterogeneity of the 
disease itself, as well as other comorbid aetiological factors, which 
adds complexity to interpretation of this data. 
(Tourney and Hatfield, 
1972; Harris et al., 2001; 
Ritsner et al., 2006, 
2007; Gallagher et al., 
2007; Strous et al., 2009; 
Babinkostova et al., 
2015) 
Multiple Sclerosis Significantly higher CSF DHEA concentrations in relapsed patients 
relative to control patients with stable neurological disease 




Increased plasma DHEA and DHEAS levels when compared to 
unaffected control patients  
(Spivak et al., 2000; 
Söndergaard et al., 2002; 
Yehuda et al., 2006; 
Bremner et al., 2007; Gill 
et al., 2008; Kellner et 
al., 2010; Jergović et al., 
2015) 
 
2.2. Process of ageing 
Ageing is an inevitable, natural biological process characterised by a progressive loss of 
physiological integrity which results in impaired function and increased probability of death. It 
is an extremely complex process which is affected by a number of lifestyle and genetic factors 
that may accelerate, ameliorate or even slow down the progression of ageing itself (Petersen 
and Smith, 2016). The process of ageing is commonly considered the main risk factor in the 
development of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s 
disease (PD) (Hindle, 2010; Niccoli and Partridge, 2012). Currently, the global population is 
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living longer as a result of the advances in medicine and consequently such diseases are 
becoming more prevalent.  
Ageing itself is associated with cumulative oxidative stress, chronic low-grade inflammation 
linked to age-related dysfunction of the immune system (termed immunosenescence) and 
most notably, a decline in endocrine function (termed endocrinosenescence) (Straub et al., 
2000; Petersen and Smith, 2016). The immediate sections to follow will focus primarily on 
immunosenescence and endocrinosenescence - highlighting their intricately linked aetiologies 
in the process of ageing itself, as well as in age-related neurodegenerative pathologies. 
2.3. Immune system maladaptation 
Inflammation is an integral part of the innate immune system: it not only acts as the first line 
of defence against pathogenic attack and injury, but also serves to execute final humoral 
immune effects (e.g. antibody-mediated pathogen destruction). It is thus a normal 
physiological process that is essential for the maintenance of homeostasis. An equally normal 
consequence of the inflammation-facilitated repair of tissues after any insult, is the transient 
disruption of the local cellular homeostasis of non-infected or uninjured cells. This injury-repair 
cycle is efficient during youthful years, but is affected by ageing, resulting in a relatively 
impaired ability of the body to regenerate damaged tissues (Petersen and Smith, 2016). 
Systemically, immunosenescent changes in the innate immune system are characterised by 
a loss of phagocytic capacity, reduced efficiency in leukocyte (neutrophil and macrophage) 
chemotaxis, reduced intracellular, but increased extracellular levels of free radicals and an 
increase in production of ”early” or acutely responsive pro-inflammatory cytokines, such as 
interleukins (IL) -1β, -6 and tumour necrosis factor (TNF) -α (Roubenoff et al., 1998; Dobbs et 
al., 1999; Wenisch et al., 2000; Guayerbas and De La Fuente, 2003), all of which contribute 
to a more pro-inflammatory phenotype and which increase the burden of tissue damage-
recovery cycles.  The loss in efficiency of this process, coupled with an increased exposure to 
antigenic load and modern lifestyle associated chronic stressors, results in the reduced ability 
of the body to maintain normal immune function.  This manifests as an increased risk for 
malignancy, auto-immune responses, an impaired ability to mount proper immune responses 
to stimuli and prolonged inflammatory activity during acute infections (Bruunsgaard et al., 








2.3.1. Neuroinflammatory changes 
As in the periphery, ageing of the brain is associated with increasing inflammation and local 
oxidative stress – also resulting in repeated tissue damage-recovery cycles - which 
predisposes older individuals to developing neurodegenerative pathologies. Age-related 
neuroinflammation partly manifests as an increased reactivity of microglia, the resident innate 
immune cells. In a healthy brain, microglia are activated upon stimulation, but do not 
necessarily release these pro-inflammatory mediators. In the aged brain however, microglia 
appear to not only release pro-inflammatory mediators, but to do so in an exaggerated and 
prolonged manner (Barrientos et al., 2012). This appears to be linked to the fact that microglia 
undergo significant immunophenotypic and functional changes with ageing: the activation 
status of microglia changes from a quiescent to a “primed” state. This manifests as an 
increased expression of the glial activation markers major histocompatibility complex II (MHC 
II) and complement receptor 3 (CD11b), which sensitizes microglia to the exaggerated pro-
inflammatory responses seen upon stimulation.  
Animal studies have also suggested that chronic and significant elevation of levels of pro-
inflammatory cytokines such as IL-1β may be linked to impaired memory formation and long 
term potentiation (LTP) (Katsuki et al., 1990; Cunningham et al., 1996; Barrientos et al., 2012; 
Gonzalez et al., 2013). Systemically, IL-1β is released by monocytes upon recognition of a 
pathogen or site of injury, as well as by any cell sustaining damage (Smith et al., 2008). IL-1β 
enhances B and T cell lymphocyte proliferation and stimulates IL-6 and TNF-α production in 
many other immune cells. The systemic elevation of circulating pro-inflammatory cytokines, 
particularly IL-1β, exerts a significant effect on microglial activation as well. However, in this 
context, the age-related maladaptation seems to occur at different magnitudes in the brain 
relative to the circulation. For example, studies in mice have shown that stimulation of the 
peripheral innate immune system with an intraperitoneal injection of either lipopolysaccharide 
(LPS) or live E.coli bacteria resulted in a more prolonged and exaggerated elevation of IL-1β 
and IL-6 levels in aged brains relative to those of younger mice (Godbout et al., 2005; 
Barrientos et al., 2009). Interestingly, the exaggerated and prolonged inflammatory response 
was restricted to the brain and not paralleled with a similar peripheral response. In addition,  it 
was reported that the hippocampus was more affected when compared to other brain regions, 
such as the hypothalamus, parietal cortex or prefrontal cortex (Barrientos et al., 2009). The 
hippocampus plays a critical role in memory formation and consequently it is implicated in 
many neurodegenerative pathologies, such as Alzheimer’s disease. These data give 
credibility to the more recent suggestions that a severe inflammatory episode may trigger 
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development of Alzheimer’s disease (Wyss-Coray, 2006; Potgieter et al., 2015). It also 
identifies the hippocampus specifically as the area of interest for preventative intervention. 
However, before one can move on to interventions, it is necessary to more fully understand 
the cause(s) of this exaggerated neuroinflammatory outcome upon ageing. A complexity is 
that the exact cause of the overactive response in microglia from aged individuals has in fact 
not been elucidated convincingly. We believe that the answer might lie in the progressive and 
chronic elevation of glucocorticoid hormones that is also associated with ageing. 
 
2.4. Endocrine Dysfunction 
2.4.1. The ageing Hypothalamic-Pituitary-Adrenal Axis (HPA)  
Cortisol released into circulation can readily cross the blood-brain barrier (BBB) and therefore 
can exert its effects both locally (in the brain) and systemically (in the periphery), by binding 
to either of its two intracellular receptors: mineralocorticoid receptor (MR) or glucocorticoid 
receptor (GR) (Barrientos et al., 2012). A study in rats showed that MRs have a significantly 
higher affinity for corticosterone (the most abundant endogenous glucocorticoid in rodents) 
than GRs; the latter is consequently only bound by corticosterone  upon complete saturation 
of MRs during periods of highly elevated serum corticosterone (Veldhuis et al., 1982). This 
phenomenon of preferential MR binding by the endogenous glucocorticoid cortisol (the most 
abundant one in humans) is also well-documented in humans (Frey et al., 2004). Binding of 
cortisol to its receptors causes it to translocate to the nucleus and decrease gene transcription 
of pro-inflammatory cytokines – effectively the body’s most important anti-inflammatory 
mechanism. The brain expresses high levels of both MRs and GRs, with highest MR 
expression mainly in the hippocampus, which has the highest MR:GR ratio in the brain overall 
(Ferrari and Magri, 2008).  
To return to the context of this review, rat hippocampal long term potentiation (LTP), a 
correlation of synaptic plasticity and strength (and thus capacity for memory formation), has 
been shown to be suppressed by GR activation (Pavlides et al., 1996), which highlights this 
pathway as role player in the pathology related to neurodegeneration, such as Alzheimer’s 
disease. The hippocampus is a brain region that is frequently highlighted in neurodegeneration 
research. Of note, and as mentioned earlier, it is affected more by peripheral inflammation 
than the rest of the brain. Therefore, should the hippocampus be specifically targeted in the 
treatment of inflammation-related neurodegeneration? In line with this question, how exactly 
do glucocorticoids link ageing, inflammation and neurodegeneration? We put forward the 
following hypothesis: as one ages, the repeated injury-repair cycles require repeated 
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glucocorticoid mediated anti-inflammatory responses. Initially, the hippocampus is sensitive to 
glucocorticoids due to a high expression of GR and MR receptors. However, after numerous 
glucocorticoid responses, the hippocampus downregulates receptor expression – something 
which is indeed seen in acute and chronic stress (López et al., 1998; Zhe et al., 2008; Smith 
and van Vuuren, 2014; Füchsl and Reber, 2016). In fact, more than 30 years ago Sapolsky 
and colleagues reported aged rats to have elevated basal corticosterone levels and an 
impaired capacity for levels to return to basal after an acute stress  response (Sapolsky et al., 
1983). This landmark paper proved to be the basis of the glucocorticoid hypothesis, which 
postulated that increasing age correlated with gradual loss of negative feedback control 
resulting in the gross accumulation of cortisol/corticosterone not only systemically, but also in 
the brain (Sapolsky et al., 1986). The loss in negative feedback may be attributed to a 
decrease in MR and GR expression in the brain. For example, in cases and animal models of 
neuropsychiatric diseases in which patients present with hypercortisolemia, such as major 
depressive disorder and PTSD, MR expression has been found to be downregulated 
specifically in the hippocampus (Zhe et al., 2008; Medina et al., 2013). A final possibility that 
we propose, is that MR and GR activation may be insensitive to glucocorticoid binding in aged 
human hippocampi. For example, it has been demonstrated in human peripheral blood 
mononuclear cells that in cells expressing high levels of GRs, GR affinity for dexamethasone 
(a synthetic corticosteroid) is significantly reduced when compared to individuals with 
peripheral blood mononuclear cells (PBMCs) with lower expression levels (Elakovic et al., 
2007).  
Given the age-related exaggerated and prolonged inflammatory responses discussed above, 
an exaggerated anti-inflammatory counter in the form of increased glucocorticoid levels is 
probably to be expected. However, the problem with the pro- and anti-inflammatory system 
crosstalk lies in that this exaggerated response, which is well-recorded in the ageing literature, 
is rendered insufficient to counter and resolve the inflammatory response by the endocrine 
maladaptation discussed here. 
2.4.2. The effect of age on the sympatho-adrenal-medullary pathway (SAM 
pathway) 
In parallel to its role in the HPA-axis, the hypothalamus also plays a critical role in the release 
of catecholamines, such as epinephrine and norepinephrine from the adrenal medulla, 
facilitated by sympathetic innervation of the medulla (Heffner, 2011). Importantly, in the 
context of this review, is the fact that catecholamines induce both the systemic and localised 
upregulation of IL-6 biosynthesis, which can prompt adrenocortical release of glucocorticoids 
(Päth et al., 1997; Johnson et al., 2005; Blandino et al., 2006, 2009; Kim et al., 2014). In 
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addition, epinephrine and norepinephrine act synergistically with cortisol by upregulating 
glucose metabolism and increasing cardiac output during acute periods of stress, i.e. the “fight 
or flight” response.  
Similar to the HPA-axis, ageing also affects the SAM pathway, mainly due to changes in the 
sympathetic nervous system (SNS). Evidently it appears that overall tonic SNS activity 
increases with age (Esler et al., 2002). Circulating norepinephrine levels appear to increase 
whereas epinephrine levels decline with age (Franco-Morselli et al., 1977; Esler et al., 1995, 
2002; Kudielka et al., 2000; Amano et al., 2013). Whether these observations are due to 
impaired clearance or an increased output by the adrenal medulla is still unknown. However, 
it is also probable that the increasing circulating concentrations of norepinephrine may in part 
be due to a spill over from synaptic junctions at effector sites – which has already been 
reported in at least one study (Esler et al., 2002).  Although no consensus has been reached 
with regard to why these changes may occur with age, it is very clear that they do occur. 
When compared to the vast knowledge gathered on the effects of age on cortisol and the HPA 
axis, relatively little is known about the SAM pathway and even less so about its effects on the 
inflammatory process. However, hormones in the SAM pathway have demonstrated immune 
modulating behaviour. For example, epinephrine has been shown to potently inhibit LPS-
stimulated human monocytes from synthesising pro-inflammatory cytokines, such as TNF-α 
and IL-12, as well as to stimulate the biosynthesis of the anti-inflammatory cytokine, IL-10 
(Elenkov et al., 2008). On the other hand, in the brain, norepinephrine may have a pro-
inflammatory effect in the hypothalamus. For example, norepinephrine was shown to play a 
critical role in foot shock stress-induced hippocampal and splenic production of IL-1β 
(Blandino et al., 2006). Pre-treatment with the selective beta-adrenergic receptor antagonist, 
propranolol, abrogated the IL-1β response. Furthermore, when animals were treated with the 
microglial inhibitor, minocycline, upregulation of IL-1β was completely inhibited in the 
hypothalamus, but not the spleen (Blandino et al., 2006). These results are extremely relevant 
in the context of ageing, since it is known that microglia play a critical role in age-related 
neuroinflammation and the fact that noradrenaline levels increase with age. 
2.4.3. The effect of ageing on sex hormones 
The HPA- and SAM-pathways are not the only endocrine systems affected by ageing. It is 
commonly known that the most evident effects of ageing occur through a decline in sex 
hormone production. With regard to a decline in androgen production and the biosynthesis 
pathways involved, the female menopause is probably best characterised - in particular, the 
complete cessation of estrogen production by the ovaries (Labrie, 2015a). Thus, after 
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menopause DHEA becomes the major androgenic hormone in the female circulation. 
Interestingly, a recent review suggested that in aged individuals, DHEA – although not able to 
facilitate ovarian estrogen production - may be able to serve as precursor for tissue-specific 
estrogen biosynthesis through intracrine mechanisms (Labrie, 2015a). According to this 
theory, estrogen would be synthesised in low concentrations at tissue level (in any tissue 
where all the required steroidogenic enzymes are present), where it would act in para- or 
autocrine fashion, with little or no clearance into circulation.  Similarly, in males, extragonadal 
male androgen production has also been demonstrated in peripheral tissue (Labrie, 2015b). 
With this in mind, a decline in adrenal DHEA production with advancing age would therefore 
not only have implications for reproduction, but also potentially for other detrimental effects 
related to a decrease in extragonadal estrogen or testosterone production at peripheral tissue 
level.   
The decline of DHEA with ageing has been well-established. Peak DHEA levels have been 
reported to occur slightly earlier in life for females when compared to males (15-19 vs. 20-24 
years) (Orentreich et al., 1984), after which it steadily declines, reaching levels of ≈20% of 
peak levels after age 70 (Rutkowski et al., 2014). Epidemiological studies have correlated 
DHEA levels to longevity in both humans and non-human models (Gaby, 1996; Roth et al., 
2002), while the decline of DHEA has been linked to a number of ageing-associated 
characteristics, including immunosenescence, cognitive decline, osteopenia and sarcopenia 
(Rutkowski et al., 2014). 
From what has already been discussed, it is clear that ageing is linked to several adaptations/ 
maladaptations in the endocrine system.  What will become equally clear from the literature to 
follow, is the relative absence of directly relevant data on DHEA, its involvement in these 
processes and thus the effects its decline might have. From studies conducted in contexts 
other than ageing, it will become clear that DHEA has a significant role to play. We discuss 




2.5. DHEA – the magic bullet?  
2.5.1. Pre-clinical evidence suggesting neuroprotective effects of DHEA 
Since the turn of the century, several papers suggesting beneficial effects after DHEA 
supplementation, in the context of neuroprotection, have been published – we have 
summarised findings illustrating the variety of models used in Table 2-2. Reported benefits 
include modulation of neurogenesis, neuronal function, metabolism and longevity. However, 
a significant limitation to available information is that the majority of these effects have only 
been illustrated in in vitro and animal studies.   
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Table 2-2:  Evidence for beneficial effects of administered DHEA/DHEAS or metabolites reported in 
pre-clinical studies 
Demonstrated beneficial effects Reference 
General neuroprotective effects demonstrated both in vitro and in vivo in:  
E18 Sprague–Dawley rat hippocampal cell culture model of N-methyl-D-aspartate (NMDA) 
neurotoxicity 
(Kimonides et al., 1998) 
HT-22 mouse hippocampal cell line model of glutamate and amyloid-β neurotoxicity (Cardounel et al., 1999) 
E18 Sprague–Dawley rat cerebral cortical cell culture anoxia model (Marx et al., 2000) 
Mouse hippocampal neurodegeneration model (Maurice et al., 2000) 
Rats with induced forebrain ischemia model (Li et al., 2001) 
Rat hippocampal slice culture ischemia model (Pringle et al., 2003) 
Primary rat cerebellar granule cell anoxic and glucose deprivation model (Kaasik et al., 2003) 
Mouse spinal cord ischemic injury model (Fiore et al., 2004) 
Rat inflammatory neurodegeneration model (Dudas et al., 2004) 
P19 neuronal NMDA-induced excitotoxicity cell line model (Xilouri and Papazafiri, 2008) 
Aged rat brain model (Kumar et al., 2008) 
Rat Corpus striatum (CS) and the nucleus accumbens (NAc) model of assessing effects of DHEA 
on monoamine oxidase (MOA) activity 
(Pérez-Neri et al., 2009) 
Human SH-SY5Y neuroblastoma cell line model assessing the effects of neurosteroids on 
mitochondrial bioenergetics 
(Grimm et al., 2014) 
Rat brain 3-Nitropropionic acid (3-NP) induced neurotoxicity model (Hanna et al., 2015) 
Transient brain ischemic mouse model (Yabuki et al., 2015) 
Primary male and female mouse cultured hippocampal neurons, as well as human SH-SY5Y 
neuroblastoma cell line glucose deprivation model 
(Vieira-Marques et al., 2016) 
Anti-apoptotic effects demonstrated in vitro in:  
Undifferentiated P19 neuronal cell line model of NMDA-induced apoptosis (Xilouri and Papazafiri, 2006) 
PC12 rat pheochromocytoma cell line model of serum deprivation-induced apoptosis in adrenal 
medulla cells 
(Charalampopoulos et al., 2004) 
Primary rat embryonic cultured neural precursor cell model investigating the effect of DHEA and 
DHEAS on Akt phosphorylation 
(Zhang et al., 2002) 
Primary rat cerebellar granule cell model of hypoxia and glucose deprivation (Kaasik et al., 2001) 
Anti-glucocorticoid effects demonstrated both in vitro and in vivo in:  
Primary rat embryonic hippocampal neurons exposed to neurotoxic doses of corticosterone (Kimonides et al., 1999) 
HT-22mouse hippocampal cell line model of glutamate and amyloid-β-induced neurotoxicity (Cardounel et al., 1999) 
Mitigating effects on corticosterone-induced suppression of neurogenesis and survival of new 
neurons in dentate gyri (hippocampi) of Lister Hooded Rats 
(Karishma and Herbert, 2002) 
Inhibitory effects of DHEA on glucocorticoid amplification in 3T3-L1 adipocyte cell line and C57BL/6J 
mouse white adipose and liver tissue  
(Apostolova et al., 2005) 
Inhibition of 11β- Hydroxysteroid Dehydrogenase 1 (11β-HSD1) mediated conversion of cortisol by 
DHEA metabolites in human skin samples 
(Hennebert et al., 2007) 
Suppression of 11β-HSD1 mRNA in HEK-293 rat cortical collecting duct cell line, as well as kidneys 
of C57BL/6J mice and Sprague-Dawley rats  





It is clear that DHEA is neuroprotective within these various disease model contexts, but how 
is DHEA relevant to inflammation – and in particular to neuroinflammation-related 
neurodegeneration?  
2.6. Direct and indirect evidence for neuroprotective anti-inflammatory 
effects of DHEA 
To the best of the authors’ knowledge, very little evidence for direct anti-inflammatory action 
of DHEA or DHEAS in the brain or central nervous system (CNS) has been elucidated per se. 
We were however able to find at least three studies that have demonstrated the anti-
inflammatory effects of DHEA in vitro in models relevant to the brain or CNS. The first 
demonstrated that DHEA inhibits the biosynthesis of TNF-α and IL- 6 by cultured foetal rat 
astroglia in response to exposure to Mycoplasma fermetans (Kipper-Galperin et al., 1999). 
The second and third studies, which are also the most recent, were performed both in vitro 
and in vivo (Alexaki et al., 2017; Boghozian et al., 2017). In the in vitro study, DHEA treatment 
of cultured mouse microglia exposed to LPS showed a significant reduction in TNF-α, IL-6, IL-
12 and Monocyte Chemoattractant Protein 1 (MCP-1) mRNA expression when compared to 
LPS exposed microglia receiving no treatment (Alexaki et al., 2017). The in vivo study was an 
experimental model of autoimmune encephalomyelitis (EAE) in mice, which showed a 
significant reduction in IL-1β and Interferon gamma (IFN-γ) mRNA expression in spinal cord 
tissue in animals treated with DHEA-S when compared to untreated EAE affected animals 
(Boghozian et al., 2017) 
Numerous other studies have illustrated the anti-inflammatory action of DHEA and DHEAS in 
systems and disease models other than those related to the brain or CNS (Table 2-3). 
Although this does not necessarily prove that these same effects may be seen in the brain 




Table 2-3: Studies which have demonstrated anti-inflammatory effects of DHEA or DHEAS outside of 
the CNS  
Disease/model Reference 
Reduced regulation of IL-6 production in aged mice  (Daynes et al., 1993) 
Reversed effects and decreased production of IL-4 and IL-6 in antigen induced 
immunosuppression in mice 
(Kim et al., 1995) 
Reduced production of IL-6 in splenocytes of retrovirus infected mice as well as 
aged-induced immunocompromised mice 
(Araghi-Niknam et al., 
1997) 
Decreased production of IL-4 and increased production of IL-2 by concanavalin-A-
stimulated PBMCs from patients with atopic dermatitis  
(Tabata et al., 1997) 
Reduction of TNF-α serum concentrations in obese Zucker rat model (Kimura et al., 1998) 
Inhibition of IL-6 production in isolated primary human peripheral blood 
mononuclear cells (PBMCs) 
(Straub et al., 1998) 
Reduced production of IL-1, IL-6 and TNF-α in LPS-stimulated murine 
macrophage cell line 
(Padgett and Loria, 1998) 
Inhibition of TNF-α-induced nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF- κB)-mediated gene transcription in HuH7 human hepatocyte cell line 
(Iwasaki et al., 2004) 
Suppression of pro-inflammatory genes (IL-1β, IL-6, TNF-α) in primary human 
HIV-positive macrophages, as well as feline immunodeficiency virus (FIV)-positive 
felines 
(Maingat et al., 2013) 
Inhibits acute LPS-induced microglia-mediated inflammation both in vivo and in 
vitro through the activation of TrkA-Akt1/2-CREB-Jmjd3 pathway and reduces IL-6, 
TNF-α, IL-12 and MCP-1 gene expression 
(Alexaki et al., 2017) 
 
From these studies it seems that DHEA exerts its anti-inflammatory effects primarily by 
modulating either the effects or production of pro-inflammatory cytokines. However, it also 
appears that the same pro-inflammatory cytokines have the ability to regulate DHEA 
production in turn. For example, in macrophage-depleted primary murine Leydig cell cultures, 
both IL-1 and TNF-α was shown to inhibit androgen steroidogenesis by downregulating the 
expression of cytochrome P450c17 mRNA – which encodes for an enzyme that is critical to 
androgen formation (Hales, 1992; Li et al., 1995). TNF-α has shown similar inhibitory effects 
in cultured porcine Leydig cells by reducing the binding of luteinising hormone (LH) or human 
chorionic gonadotropin (hCG) to the respective receptor – which would stimulate 
steroidogenesis (Mauduit et al., 1991). These authors further suggested that the primary 
inhibitory effect of TNF-α was mainly by decreasing availability of cholesterol, the initial 
substrate required for steroidogenesis (Mauduit et al., 1991). 
Regardless of how cytokines may inhibit the biosynthesis of androgens, these studies provide 
a plausible explanation for the age-related decline of DHEA not only systemically, but centrally 
as well – given the relatively pro-inflammatory status associated with ageing. Furthermore, 
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since it has been shown that the inflammatory maladaptation seen with ageing affects the 
brain to a larger extent (specifically the hippocampus), it is plausible that the age-related 
decline of DHEA occurs even more rapidly in the brain than it does in the rest of the body. 
In contrast to the idea that DHEA is largely beneficial, a minority of studies have suggested 
that DHEA may have neurotoxicity under specific conditions. In a model of global cerebral 
ischaemic insult in rats (Li et al., 2009),  intraperitoneal administration of a supraphysiological 
dose of DHEA 3 to 48 hours after ischaemic injury was neuroprotective (e.g. decreased 
neuronal death in the CA1 hippocampal region). However, DHEA administration 1 hour before 
or after the insult, exacerbated the effects of the injury. Given the known anti-inflammatory 
role of DHEA, this may suggest that (at least at this high dose) DHEA inhibited early 
inflammatory or oxidative responses that were required for cytoprotection. Additionally, 
decreased cell viability was reported in primary murine neuronal cultures and human 
neuroblastoma (SK-N-SH) cells after (24-72hr) exposure to a large dose-range of DHEA – a 
result not seen in mixed neural or glial cultures. Furthermore, the neurotoxic effects of DHEA 
were abrogated by simultaneous treatment with DHEAS (Gil-ad et al., 2001). From this, it is 
difficult to formulate an interpretation on potentially toxic effects of DHEA. On the one hand, it 
is certainly feasible that a high dose of an antioxidant such as DHEA may have damaging 
effects, as this has been illustrated in the nutraceutical literature (Burkitt, 2001). On the other 
hand, the second study clearly highlights the limitations of interpretations possible from single 
cell culture models, although it does provide insight on the complexity of the mechanisms at 
play. In our opinion, given the relatively larger body of evidence in support of a beneficial effect 
of DHEA, significant concern is probably not warranted in our context of intracrine DHEA 
production. 
In order to further our understanding of how DHEA may impact on the ageing brain, it is 
necessary to delve deeper into the potential molecular actions and interactions of DHEA and 
DHEAS. 
2.7. Potential mechanisms for DHEA-mediated neuroprotective effects   
There are at least two ways via which DHEA can facilitate its effects centrally. Through 
following the conventional steroidogenesis pathway, DHEA may be converted to endpoint sex 
hormones, which would then activate their respective receptors. Reviews by different groups 
have suggested that DHEA can elicit genomic effects through its conversion into testosterone 
and dihydrotestosterone (DHT) – thereby activating androgen receptors (AR) – as well as 
through its conversion into estradiol and the subsequent activation of estrogen receptors (ER) 
(Stárka et al., 2015; Arbo et al., 2016). In support of this suggestion, It has indeed been 
demonstrated that isolated neonatal rat cortical and hypothalamic astrocytes can synthesize 
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both testosterone and estrogen from exogenous DHEA (Zwain and Yen, 1999a). Alternatively, 
DHEA itself may be able to directly bind to and activate these hormone receptors. Although 
no cell membrane-bound or nuclear receptor has been described to have an affinity 
specifically for DHEA or DHEAS, a recent comprehensive review has revealed that DHEA and 
DHEAS have affinity for a number of membrane and nuclear receptors and binding sites 
(Prough et al., 2016), allowing DHEA to directly activate receptors in the brain and CNS 
specifically. DHEA is known to interact with the cell membrane receptors γ-aminobutyric acid 
type A (GABAA), N-methyl-D-aspartate (NMDA) and Sigma-1 (σ-1), as well as nuclear 
receptors such as peroxisome proliferator-activated receptor  (PPAR) -α and finally 
neurotrophin receptors such as Tyrosine receptor kinase (Trk)  -A, -B and -C (Lazaridis et al., 
2011; Pediaditakis et al., 2015; Prough et al., 2016; Alexaki et al., 2017). These potential 
mechanisms are briefly discussed in the following paragraphs. 
Firstly, GABAA receptors are ligand-gated chloride and bicarbonate channels that induce 
hyperpolarisation to inhibit the postsynaptic potentials when activated (Prough et al., 2016). 
DHEA and DHEAS (to a greater extent) have both been shown to act as non-competitive 
antagonists of ionotropic GABAA receptor-mediated activity in isolated neurosynaptosomes 
from Sprague-Dawley rat brains (Imamura and Prasad, 1998). Similarly, DHEAS was shown 
to block recombinant GABAA receptor (GABAA R) -mediated currents in transfected HEK293 
cells (Švob Štrac et al., 2012; Sachidanandan and Bera, 2015). Another study of reversible 
spinal cord injury in rabbits showed that DHEAS significantly delayed the onset of ischemia-
induced paraplegia (Lapchak et al., 2000). However, despite widely reported, the exact 
mechanisms of how DHEA or DHEAS may elicit neuroprotective effects through GABAA 
receptors still remain to be fully elucidated. It is important to point out that DHEA appears to 
induce multiple effects through GABA receptors – of note and in the context of ischemia 
injuries it demonstrates antioxidant capacity, which is already accepted in literature and 
highlights the beneficial pleiotropic effects of DHEA.  
Secondly, the NMDA receptor (NMDAR) is a cell membrane bound receptor that is a member 
of a large family of glutamate receptors. Glutamate receptors bind to neurotransmitters and 
allosteric effectors which regulate transmembrane ion channels involved in learning and 
memory, i.e. LTP (Prough et al., 2016). DHEAS has been shown to activate NMDARs in both 
rat hippocampal slices and cultured mouse embryonic cultured neocortical neurons (Monnet 
et al., 1995a; Compagnone and Mellon, 1998). These reports suggest a more active function 
of DHEA in the context of NMDARs.  
Thirdly, Sigma-1 (σ-1) receptors are associated with cellular membranes, endoplasmic 
reticulum, nuclear membranes and mitochondrial membranes of many cells of neural origin, 
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including astrocytes, oligodendrocytes and microglia (Prough et al., 2016). DHEA activation 
of sigma-1 receptors improved memory deficits induced in mouse models (Meunier and 
Maurice, 2004). In addition, the effect that DHEA and DHEAS has on NMDARs appears to be 
linked to sigma-1 receptor interactions. Evidence has shown that DHEAS can potentiate 
NMDA evoked release of norepinephrine in rat hippocampal brain slices through its action as 
a sigma-1 agonist (Monnet et al., 1995b).  
Fourthly, peroxisome proliferator-activated receptors or PPARs are nuclear associated 
transcription factors that are capable of exerting pleiotropic physiological effects, such as 
regulating lipid metabolism, participating in glucose homeostasis and even having a role in 
apoptosis (Stahel et al., 2008). DHEA and DHEAS may exert neuroprotective effects at 
nuclear receptors such as PPARα. Specifically, inhibiting NF-kB binding to PPARα. In a rodent 
study, the effects of DHEA and DHEAS treatment in aged wild type (PPARα+/+) vs aged 
PPARα knockout mice (PPARα-/-) were investigated. The aged wild type mice treated with 
DHEA and DHEAS exhibited reduced tissue lipid peroxidation, reduced NF-kB activation in 
the spleen and lower pro-inflammatory cytokine production when compared to knockout mice 
also treated with DHEA and DHEAS (Poynter and Daynes, 1998). It is worth noting though 
that no specific binding affinity of PPAR for DHEA or DHEAS has been reported (Peters et al., 
1996). Despite this fact, PPARα receptors have increasingly been reported to have a role in 
mediating oxidative stress and inflammation in brain pathologies such as traumatic brain injury 
(TBI) (Feng et al., 2008; Stahel et al., 2008). 
In line with these mechanisms, DHEA has been shown to activate the pro-survival 
Phosphatidylinositol-4,5-bisphosphate 3-kinase/Protein Kinase B (PI3/Akt) pathway. In fact, a 
study investigating the effects of NMDA-induced excitotoxicity in culture mouse brain cells, 
illustrated that DHEA was able to mitigate the detrimental effects by activating the PI3/Akt 
pathway through a calcium dependent mechanism (Xilouri and Papazafiri, 2008). Similarly, 
DHEA supplementation in aged Wistar rats was able to increase the expression of 
phosphorylated-Akt in liver tissue (Jacob et al., 2011).  
In terms of neurotrophin receptors, DHEA has been shown to bind with high affinity to the 
Nerve Growth Factor (NGF) receptor TrkA  in HEK293 cells transfected with TrkA plasmid 
cDNA (Lazaridis et al., 2011). Binding of DHEA to TrkA led to phosphorylation of the receptor 
and activation of downstream pathways such as the Akt, extracellular signal-regulated kinases 
(ERK) -1/2 and SHC-transforming protein (Shc) signalling cascades (Lazaridis et al., 2011). 
In a similar study, also conducted in transgenic HEK293 cells, DHEA was shown to also bind 
to TrkB, which is mainly activated by brain derived neurotrophin factor (BDNF), and TrkC, 
which is preferentially activated by neurotrophin-3 (NT-3) (Pediaditakis et al., 2015). However, 
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this study showed that DHEA binding only led to the phosphorylation and activation of TrkC, 
but not TrkB (Pediaditakis et al., 2015). It was noted that DHEA bound these receptors by two 
orders magnitude lower than that of the inherent neurotrophins. 
Finally, DHEA may also have a modulatory role in cytoskeletal dynamics. In this context, 
DHEA has been found to bind to the N-terminal of the dendritic localised microtubule 
associated protein type 2C (MAP2C). MAPs bind to and facilitate the dynamic microtubulin 
polymerisation and DHEA was reported to increase the length of dendrites expressing MAP2C 
(Laurine et al., 2003). This finding is of particular relevance in the context of neurodegenerative 
pathologies such as AD where a pathological change in neuritic morphology is associated with 
disease (Nixon et al., 2005).  
Taken together, these studies indicate a significant modulatory role of DHEA/DHEAS via its 
binding to a wide variety of receptors. Of particular relevance to the current topic, DHEA-linked 
anti-inflammatory – albeit mainly demonstrated in circulation – and neuroprotective outcomes 
indirectly suggest that several benefits may come from prevention of DHEA decline. 




2.8. Efficacy of therapeutic DHEA administration  
DHEA supplementation has historically been used in the treatment of reproductive-related 
diseases, particularly in women, where it has been shown to alleviate menopause-related 
pathologies such as vaginal atrophy (Labrie et al., 2009). In support of our interpretation of 
benefit from maintaining DHEA availability, in diseases not related to reproduction, DHEA 
supplementation has been shown to be beneficial to both sexes in the treatment of numerous 
other pathologies or conditions (see Table 2-4).  
 
Table 2-4: Illustrating the variety of studies reporting favourable effects of DHEA/DHEAS 
supplementation in clinical pathologies 
Disease State References 
Autoimmune disease  
Systemic Lupus Erythematosus (van Vollenhoven et al., 1994, 1995, 1998, 1999; Barry 
et al., 1998; Chang et al., 2002; Petri et al., 2002, 
2004; Sánchez-Guerrero et al., 2008) 
Metabolic disease  
Hypercholesterolemia (Felt and Stárka, 1966) 
Metabolic Syndrome (Villareal and Holloszy, 2004) 
Genetic diseases  
Hereditary Angioedema (Koó et al., 1983) 
Ageing-associated  
Advanced age (Morales et al., 1994, 1998) 
Osteoporosis (Sun et al., 2002; von Mühlen et al., 2008) 
Endocrine disorders  
Hypopituitarism (Johannsson et al., 2002; Bilger et al., 2005; Brooke et 
al., 2006a, 2006b) 
Adrenal Insufficiency/Addison’s disease (Arlt et al., 1999; Gebre-Medhin et al., 2000; Hunt et 
al., 2000; Callies et al., 2001; Libè et al., 2004; 
Dhatariya et al., 2005; van Thiel et al., 2005; Gurnell 





Despite these many clinical studies involving DHEA supplementation, to the best of the 
authors’ knowledge, the effects of exogenous DHEA supplementation has not been directly 
assessed in clinical manifestations of neurodegeneration or any related pathologies. Similarly, 
there are also currently no clinical studies assessing the effects of DHEA or DHEAS 
supplementation as an adjuvant therapy for neurodegenerative diseases in either the 
European or American clinical trial database. 
In addition, it should be noted that other studies have reported oral DHEA supplementation to 
show little to no benefit in the treatment of other ageing-related pathologies such as cognitive 
performance, lipid metabolism, glucose metabolism, bone health and muscle function (Wolf et 
al., 1997; Percheron et al., 2003; Corona et al., 2013). 
However, the available clinical studies collectively do provide some insight. The conditions 
included in our summary (Table 4), which all suggests benefit from DHEA administration, are 
linked by the fact that inflammation is a characteristic feature in all. Similarly, 
neuroinflammation is a critical hallmark of the generalised pathophysiology of 
neurodegeneration and its occurrence appears to have a causative role in this degenerative 
condition.  Thus, given the already discussed anti-inflammatory effect of DHEA (refer to Table 
3), as well as the anti-inflammatory therapeutic effect suggested by the results just presented, 
theoretically, if one can increase DHEA production at cellular level in the central compartment, 
one should be able to alleviate or prevent neuroinflammation and thus neurodegeneration.  
2.9. Is it possible to stimulate extragonadal biosynthesis of DHEA or DHEAS? 
Since exogenous DHEA supplementation has yielded varying benefit, an obvious alternative 
therapeutic – or preventative – strategy to consider is whether it might be naturally or artificially 
possible to increase endogenous DHEA production.  
From the sport and exercise literature, it is known that exercise in older males can significantly 
increase serum DHEA and DHEAS concentrations (Boudou et al., 2000; Ravaglia et al., 2001; 
Tissandier et al., 2001; Tremblay et al., 2004; Arai et al., 2006; Cadore et al., 2008; Heaney 
et al., 2013). These results do not provide proof of extragonadal androgen biosynthesis 
though, as moderate exercise is known to increase gonadal testosterone production. 
However, interestingly, similar effects of exercise has been reported for DHEA in older, post-
menopausal females (Copeland et al., 2002; Giannopoulou et al., 2003; Kemmler et al., 2003). 
In this population, where gonadal androgen production is less possible, it is possible that 
extragonadal DHEA production may occur in response to exercise.  
Interestingly, a study conducted in Sprague-Dawley rats has illustrated skeletal muscle to have  
endogenous steroidogenic capacity and that acute bouts of aerobic exercise can significantly 
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enhance the localised production of DHEA in both male and female animals  (Aizawa et al., 
2010). This adds substantial support for our theory that extragonadal DHEA biosynthesis may 
be elicited through intervention.   
Furthermore, higher DHEAS levels have been reported in long-term practitioners of alternative 
therapies such as transcendental meditation and the ancient martial art of tai chi, when 
compared to age-matched controls (Glaser et al., 1992; Lai et al., 2017). Although these 
studies do not prove that DHEA production is stimulated by these practises, the relatively 
higher levels suggest at least an effect to sustain long-term production rate.  In line with these 
results obtained in psychology-based practices, environmental enrichment in caged rats was 
linked to increases in steroidogenic enzyme expression associated with DHEA production, 
relative to unstimulated rats of the same age (Rossetti et al., 2015). Indeed, enrichment 
therapy is already being employed to treat patients with dementia and Alzheimer’s disease 
(da Cruz et al., 2015; Matias-Guiu et al., 2016; Quintana-Hernandez et al., 2016; Sanchez et 
al., 2016; Garcia-Casal et al., 2017), although the authors could not find data on the effect of 
this strategy on DHEA biosynthesis. 
Considering this evidence, perhaps it is necessary to first understand which tissues may 
possess the ability for DHEA biosynthesis, before considering the feasibility of this approach 
in the context of neurodegeneration. 
2.10.  DHEA Biosynthesis   
DHEA is produced during steroidogenesis, in a manner dependent on mainly two classes of 
steroidogenic enzymes; namely the P450 enzymes and the hydroxysteroid dehydrogenases 
(Miller et al., 2007). Also, DHEA can be sulphated into DHEAS via enzymes called steroid 
sulphotransferases (SULT), while conversion of DHEAS back into DHEA is mediated via 
steroid sulphatases (STS). DHEAS levels continue to increase after puberty, peaking in the 
mid-20s, after which levels begin to progressively decline with age in both men and women 
(Orentreich et al., 1984; Maninger et al., 2009). Serum DHEA and DHEAS levels are thought 
to be almost exclusively maintained by their biosynthesis in the adrenal zona reticularis (Miller 
et al., 2007). However, in theory any tissue that expresses the steroid enzymes can be 
classified as steroidogenic. In fact, in the early 80s Fernand Labrie, a well-known 
endocrinologist, was the first to note that prostate glands of patients with prostate cancer still 
had high levels of dihydrotestosterone (DHT) even after castration (Labrie, 2010). He 
illustrated that some peripheral tissues, such as the prostate, possesses the steroidogenic 
enzymes needed to transform DHEA and DHEAS into its androgenic and estrogenic 
metabolites, thereby capable of exerting a relatively more localised effect. The study of this 
unique ability of peripheral tissues was termed “intracrinology” and has subsequently gained 
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some momentum (Re, 2014). Given the importance of intracrine derived hormone production 
in terms of female reproductive health, it is clear that investigations into intracrinological 
mechanisms in other contexts are warranted, such as in neurodegeneration and ageing. 
Although it is known that intracrinology takes place in peripheral tissues, all tissue types do 
not express the same isoforms of the steroidogenic enzymes, nor are they expressed in the 
same quantity or constitutively expressed as we age. For example, a recent study in rats 
demonstrated that the expression of several steroidogenic enzymes decline significantly in the 
brain with age (Rossetti et al., 2015). It is important to have an understanding of where the 
capacity for steroidogenesis exist, as well as to consider sex and species differences, as these 
aspects significantly impact on choices for experimental models, as well as on the relevance 
and applicability of research data gained in any particular model. It is not possible to address 
steroidogenesis in its totality within the scope of this review. Rather, in the next few sections 
we describe some of these intricacies in the context of DHEA biosynthesis specifically. 
2.11.  Production sites of DHEA 
In terms of substrate delivery for steroidogenesis, the Steroidogenic Acute Regulatory Protein 
(StAR) and cholesterol side-chain cleavage enzyme (P450scc) are required for the transport 
of cholesterol to the mitochondria and conversion into pregnenolone (P5), respectively. 
Interestingly, these enzymes are expressed at significantly lower levels in the Leydig cells of 
aged rat testes relative to those of younger rats (Luo et al., 2001), which - since Leydig cells 
are the primary cells for testosterone production in the male body -  provides a plausible 
explanation for the age-related decline of the hormone in both rodents and humans. 
Interestingly, in contrast, P450scc protein and mRNA expression in the human adrenal glands 





















Figure 2-1: Representative diagram of reported steroidogenic enzyme expression reported in different brain cell types. Species employed were rat, 

























































































(Gottfried-Blackmore et al., 2008) 
(Melcangi et al., 1993; Zwain & Yen, 1999a, 1999b; 
Lovelace et al., 2003; Karri et al., 2007; Mizoguchi et al., 2009) 
(Melcangi et al., 1993; Zwain & Yen, 1999b) 
(Melcangi et al., 1993; Zwain & Yen, 1999b; 
 Mizoguchi et al., 2014) 
(Geerling et al., 2006) 
(Benmessahel et al., 2004) 
(Kimoto et al., 2001; Shibuya et al., 2003;  
Mukai et al., 2006) 
(Ukena et al., 1998, 1999; Yarim & Kabakci, 2004;  
Griffin et al., 2004) 
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In the context of central intracrine production of DHEA, P450scc mRNA has been detected in 
cultured human astrocytes and oligodendrocytes (but not neurons) in at least one study 
(Brown et al., 2000). Many other studies have detected steroidogenic enzyme expression in 
both neurons and neuroglial cells in vertebrates other than humans (Fig. 2-1). We tabulated 
these studies for brevity, but it is important to note that although steroidogenic enzyme mRNA 
was detectable in these different animal brain cell types, it is not clearly indicated to what 
extent the level of gene expression may differ from one cell type to another. Our interpretation 
of the data presented in most of these cited studies, is that neuroglial cells appear to express 
higher levels of steroidogenic enzyme mRNA relative to neurons, where levels were barely 
detectable in some cases. This suggests that mainly neuroglial cells are capable of significant 
intracrine biosynthesis, as already reported for peripheral tissue other than gonads and 
adrenals (Labrie, 2015a, 2015b). In contrast to the P450scc findings, StAR mRNA expression 
in rat brains has been shown to indeed decline significantly with age (Sierra et al., 2003), 
suggesting a relative decline in substrate delivery similar to that reported for the testis. 
Whether this occurs in human brain tissue could not conclusively be answered from the 
literature, but it certainly cannot be ruled out. Nevertheless, the presence of both StAR and 
P450scc in astrocytes and oligodendrocytes argues in favour of sufficient substrate availability 
to indeed allow for localised production of DHEA in these cells. 
Another protein of potential relevance in the context of cholesterol transport to the 
mitochondria has been described. Translocator protein (TSPO), also known as peripheral-
type benzodiazepine receptor (PBR), a protein mainly bound to the outer mitochondrial 
membrane, has also been suggested to play a role in the facilitation of cholesterol transport 
via StAR (Lacapère and Papadopoulos, 2003). Whether the presence of TSPO is critical in 
the transport of cholesterol is a matter of controversy within literature. It was shown in mice, 
with a specific TSPO gene knockout in their Leydig cells, that testosterone could still be 
produced despite the absence of what thought to be a critical protein for the process 
(Morohaku et al., 2014). Despite the uncertainty surrounding its role in steroidogenesis, TSPO 
has recently been identified as a potential biomarker of neurodegeneration, as its expression 
increases with inflammation and neurodegeneration associated with Alzheimer’s disease, HIV 
encephalitis and MS (Cosenza-Nashat et al., 2009; Kreisl et al., 2013). 
More specifically in terms of its function centrally, in vitro experiments in primary human 
astrocytes have demonstrated that various synthetic TSPO ligands of the N,N-dialkyl-2-
phenylindol-3-ylglyoxylamide class (PIGAs) are capable of activating TSPO activity and 
stimulating neurosteroidogenesis (Da Pozzo et al., 2016). In fact, PIGAs have shown to be 
neuroprotective in L-buthionine-(S,R)-sulfoximine (BOS) induced cytotoxicity of C6 rat glioma 
cells (Santoro et al., 2016). The mechanism of neuroprotection was associated with a 
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reduction in lipid peroxidation and inflammation, which was abrogated in presence of the 
P450scc and StAR inhibitor aminoglutethimide and was therefore thought to occur due to 
steroidogenesis.  Given the known anti-inflammatory and antioxidant properties of DHEA, 
TSPO may be a role player in the maintenance of DHEA levels. 
Another fact in favour of local DHEA production in the brain, is the relatively increased demand 
for DHEA in brain relative to the periphery. Firstly, steroid sulphotransferase isoform 2A1 
(SULT2A1) – which increases circulating DHEAS by sulphating DHEA, rendering it bio-
inactive (Suzuki et al., 2000) – seems to not be present in brain tissue at all, while SULT2B1 
expression has only been reported for the prefrontal cortex, hippocampus and cerebellum, but 
not for the cerebral subcortex or neocortex (Steckelbroeck et al., 2004; Lin et al., 2014). 
Secondly, sulphatase (STS) expression – which is responsible for conversion of DHEAS into 
the bioactive DHEA -  is generally very high in the CNS (Stárka et al., 2015). Together, this 
suggests a relatively higher demand for DHEA in the brain when compared to the periphery. 
This scenario would also increase the likelihood of mechanisms for local production to be in 
place.  
The idea of de novo biosynthesis of DHEA and DHEAS in the brain itself remains a highly 
debated topic in the field. As mentioned, the human adrenal glands were initially thought to be 
the only site of endogenous steroidogenesis, apart from the gonads (i.e. testes, ovaries) which 
produce DHEA and DHEAS to a lesser extent. However, the brain has recently and 
controversially been highlighted as a possible alternative site for production. Given the 
neuroprotective and central anti-inflammatory effects of DHEA already discussed, this 
possibility for intracrine DHEA production has far-reaching implications for both 
neurodegenerative disease and ageing – not only to increase our understanding of the disease 
processes, but also in terms of development of preventative and/or therapeutic strategies.  
The first suggestion of DHEA biosynthesis in the brain was already published in the 1980s – 
when  DHEA and DHEAS concentrations were reported to be higher in rat brains than in 
circulation (Corpéchot et al., 1981). A few years later, similar circumstantial evidence for DHEA 
biosynthesis in the human brain emerged (Lacroix et al., 1987). DHEA was subsequently 
commonly referred to as a “neurosteroid”, based on its relatively increased central localisation. 
Although DHEA can be detected in both animal and human brain tissue, it remains unclear 
whether de novo biosynthesis indeed occurs. For evident reasons, it is practically difficult to 
accurately assess actual DHEA production in the human brain, so that most data are 
generated from rodent models. To add complexity to this topic, subsequent evidence may 
suggest that a species-difference in terms of central DHEA levels may exist. In terms of 
criticism of analytical techniques, it has for example been suggested that DHEA levels in rat 
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brain tissue reported in earlier studies may have been overestimated due to a lack of sensitivity 
of the radio-immunoassays (RIA) technique used at the time, which relied on antibody 
specificity to detect the steroid hormones (Liere et al., 2000). A newer method encompassing 
solid phase extraction (SPE), high performance liquid chromatography (HPLC) and gas 
chromatography-mass spectrometry (GC-MS) was developed to generate more accurate data 
(Liere et al., 2000). Ironically, nearly a decade later it was reported by the same authors that 
this technique may indeed also be flawed when it came to the detection of sulphated steroids 
(Liere et al., 2009). They showed in rodent samples that the levels of DHEA and P5 were 
higher in the lipoidal fraction of the SPE. It was suggested that cholesterol contamination may 
have contributed to these findings through cholesterol autoxidation, generating  DHEA and 
P5, and that actual  levels of DHEA and DHEAS are likely extremely low or essentially non-
existent in rat brain tissue (Liere et al., 2009). Interestingly, in the same paper, the authors 
were able to confirm the presence of significant amounts of both DHEA and P5 in human brain 
tissue samples using this improved methodology. The exact mechanisms of how cholesterol 
autoxidation leads to DHEA and P5 generation remains to be elucidated. Nevertheless, these 
results highlight the necessity of considering species in the design of experimental models. 
The fact that DHEA cannot be detected in rodent brains may be a function of generally lower 
levels when compared to humans. Thus, although rodents can still be feasible models, the 
parameters to be assessed, might have to differ depending on analytical sensitivity.  
Given these methodological limitations in the measurement of hormone levels directly, many 
indirect methods have been employed to investigate the possibility of DHEA production 
centrally. However, results have again posed more questions than answers. For example, on 
one hand, P450c17 mRNA – which transcribes an enzyme that is crucial in the formation of 
DHEA – has been detected in cultured human glial cells (Brown et al., 2000). Subsequently, 
P450c17 mRNA expression has also been demonstrated in the amygdala, caudate nucleus, 
cerebellum, corpus callosum, hippocampus and thalamus of the human brain (Yu et al., 2002). 
In addition and similarly to circulating DHEA levels, the enzyme expression also declines with 
age in the rat brain, which argue in favour of the possibility for local DHEA biosynthesis 
(Munetomo et al., 2015). Interestingly, the age-related decline in P450c17 mRNA was reported 
to be more pronounced in the cerebral cortex and cerebellum, but not the hypothalamus 
(Munetomo et al., 2015) – this fact should be further explored in order to determine its 
relevance.  
However,  the expression of P450c17 in the human brain has been a topic of debate – at least 
two other studies could not detect any P450c17 mRNA in the human cerebellum, 
hippocampus or temporal lobe and reported no P450c17 activity in the temporal lobe 
(Steckelbroeck et al., 2004; MacKenzie et al., 2008). There are a variety of possible 
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explanations for these different results. Firstly, it is known that age has a significant effect on 
steroidogenic enzyme expression, so it is possible that this may have affected the results. 
Indeed, in the study where the P450c17 mRNA was detected, samples were pooled from 
patients between the ages of 10 to 78 years. On the other hand, in at least one of the studies 
failing to detect enzyme activity,  samples were collected from a much older patient cohort (80 
years and older) (Yu et al., 2002; MacKenzie et al., 2008). Secondly, in terms of the failure of 
any group to report activity of the enzymes which catalyse the reaction in the brain (Stárka et 
al., 2015), there is currently no way to determine at which rate potential local DHEA 
biosynthesis would occur. An important consideration here is that  P450c17 expression 
reported for the CNS is substantially lower than for the testes, which exceeds it by nearly 200-
fold (Stárka et al., 2015). It is therefore likely that the conventional methods previously 
employed in studies with negative outcome, may not have been sufficiently sensitive to detect 
these possibly very low levels of activity. Thus, the issue remains to be elucidated across the 
ageing spectrum, to eliminate the potential for a false negative outcome by using aged 
individuals. 
Additionally, it is possible that localised DHEA biosynthetic mechanism in the brain may differ 
from that at other sites of local DHEA production. One group has indeed suggested that DHEA 
and DHEAS can be synthesised in a manner independent of P450c17. Their evidence 
suggests that cultured human astrocytes and oligodendrocytes, but not neurons, could 
synthesize DHEA in the presence of a P450c17 and 3β-HSD inhibitor. It is suggested that this 
alternative pathway may be dependent on reactive oxygen species and produce DHEA from 
an unknown “precursor” molecule other than P5 (Brown et al., 2000). Although this study 
provided interesting data, there is a limitation to the scientific rationale, as the authors admitted 
that the P450c17 inhibitor used could not block endogenous DHEA production in the glial cells.  
At least one other lab has also speculated on the possibility for an alternative pathway of 
DHEA production linked to free radicals (Maayan et al., 2005). This is not impossible, since a 
precedent in this regard exists: an alternative steroid production mechanisms in the brain was 
clearly demonstrated in the case of 21-hydroxylation, which appears to be mediated through 
CYP2D instead of CYPC21 (Kishimoto et al., 2004).   
Apart from the debate on the capacity for intracrine DHEA biosynthesis in the CNS, several 
theories have been formulated in attempts to explain the relatively higher DHEA and DHEAS 
concentrations in the central compartment. For example, it has been suggested that DHEA in 
the brain may be produced from DHEAS delivered from circulation, through conversion by 
steroid sulphatase (STS). Indeed, it has been shown that the human temporal lobe expresses 
high amounts of STS mRNA as well as activity in the cerebral cortex relative to subcortical 
white matter (Steckelbroeck et al., 2004). However, there are two arguments against this 
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hypothesis. Firstly, sulphated hydroxysteroids such as DHEAS are hydrophilic and do not 
readily cross the blood-brain barrier (Kishimoto and Hoshi, 1972).  Although sulphated steroids 
such as DHEAS and P5 sulphate may enter the brain through circulation via organic anion 
transporting peptides (OATP) transporting them both ways, it would appear that OATP 
transport of sulphated steroids favours movement out of the CNS, not in (Asaba et al., 2000). 
However, a recent study investigating the transport of DHEAS and P5S through the blood 
brain barrier (BBB) of rats found that although P5S entered the blood brain barrier more 
readily, DHEA was rapidly metabolised into androstenedione (A4) and androstenediol (Qaiser 
et al., 2017). Further investigation found that the enzymes responsible for the rapid 
desulphatasion were mainly localised in the BBB capillaries as opposed to the brain 
parenchyma (Qaiser et al., 2017). This argues that the DHEA in brain is likely from peripheral 
sources as opposed to de novo biosynthesis. However, it is important to note that the overall 
efflux of DHEAS through the BBB may still not be rapid enough to account for the differences 
in concentration in the brain versus the periphery. 
Secondly, as already mentioned, DHEA and DHEAS concentrations have been reported to be 
markedly higher in the human brain than in circulation (Lacroix et al., 1987). In this study, 
DHEA concentrations were determined in the brains of 10 subjects (9 females and 1 male, 
ages ranging from 80 – 93). Nevertheless, in rat brains DHEA concentrations were higher 
relative to circulation and remained so even 15 days after an adrenalectomy and/or 
orchiectomy (Corpéchot et al., 1981). This argues against the idea of systemic delivery. 
However, as mentioned earlier the techniques that were used to determine the concentration 
of DHEA in these studies may reassessed due to possible cholesterol contamination. 
Taken together there still exists a strong body of evidence to support that de novo biosynthesis 
occurs in the brain. Although it is near impossible to prove this specifically in humans, as one 
will be faced with clear practical and ethical hindrances, it is the opinion of the authors that the 
human brain does indeed produce DHEA centrally. In order to understand how DHEA may be 
produced in the brain, the use of animal models may be the only way to elucidate key 
pathways. This, however, does not come without its challenges. 
2.12. Practical challenges in steroidogenesis research 
Several practical challenges have already been alluded to in this review, such as 
methodological issues pertaining to mRNA and protein determination, as well as gender-
specificity. A remaining consideration which will be touched on in this section, is the 




















































Figure 2-2: The process of steroidogenesis in rodents and humans. Cytochrome P450 enzymes (blue font), Hydroxysteroid dehydrogenases (orange font), 
Reductases (purple font), and Steroid Sulphatases (yellow font) and Sulphotransferases (green font).  Part of the pathway highlighted in green denotes the Δ5 
pathway, which is favoured in human steroidogenesis, and the blue denotes the Δ4, which is favoured in rodent steroidogenesis. 
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For example, it is important to consider that systemic steroidogenesis in humans, higher 
primates and bovines differ from rodents in two significant ways. Firstly, humans primarily 
convert pregnenolone (P5) to androstenedione (A4) through the Δ5 pathway in the following 
manner: P5 » 17OH-P5 » DHEA » A4. Rodent steroidogenesis on the other hand favours the 
Δ4 pathway; P5 » progesterone (P4) » 17OH-progesterone (17OHP4) » A4 (Fig. 2-2). This is 
speculated to be the reason why humans have high levels of circulating DHEAS, while in 
rodents levels are significantly lower when compared to humans (van Weerden et al., 1992; 
Pluchino et al., 2015).  
Secondly, in humans the adrenal gland is the main source of DHEA production, but in rodents 
the gonads are the main source, as the adrenal glands of most species mice and rats appear 
to lack P450c17 enzyme activity (Le Goascogne et al., 1991; van Weerden et al., 1992). 
Although human gonads do produce androgens such as DHEA, the reason for adrenal 
preference of androgen production is not clear. The use of rodent models in studying the 
systemic role DHEA has thus garnered concern due the significant differences between 
humans and rodents. However, the fact that DHEAS has been found in both human and rodent 
brain tissue suggests that potential for de novo DHEA production exists in the brain in both 
species. Therefore, rodents could still serve as reliable model systems in studying DHEA and 
its role in the brain.  
Of specific interest in this context, it was recently discovered that the precocial species of 
mouse, Acomys cahirinus or Spiny mouse, possess adrenal glands that express P450c17 and 
are in fact capable of producing DHEA (Quinn et al., 2013, 2014). This unique mouse has a 
longer gestational period (± 39 days) when compared to other mice and rats and unlike other 
rodents, has a brain growth pattern that is comparable with humans at the time of birth (Brunjes 
et al., 1989; Quinn et al., 2016b). It has also been shown in spiny mice that cortisol is the main 
glucocorticoid in the blood, unlike in rats where corticosterone is the main circulating 
glucocorticoid (Quinn et al., 2013, 2014). Most importantly, explanted foetal, neonate and adult 
spiny mouse brain tissue in culture have been shown capable of producing DHEA in the 
presence of P5 (Quinn et al., 2016a). In addition, spiny mouse also exhibit an age-related 
decline in DHEA biosynthesis (Quinn et al., 2016b). These mice may prove to be a particularly 








Based on the successes reported in experimental model systems, DHEA has been proven to 
be beneficial to limit progression of various inflammation-associated neurodegenerative 
diseases. From our review of the relevant literature, we conclude that central, intracrine 
biosynthesis of DHEA is highly probable and we have highlighted several mechanisms by 
which locally synthesised DHEA may affect preventative and/or therapeutic benefit in the 
context of neurodegeneration. Current literature is limited by controversies regarding 
methodological accuracy and the suitability of basic neuronal cell culture models.  
2.14. Problem Statement 
Although substantial evidence exists demonstrating the beneficial effects of DHEA in various 
disease contexts – especially neurodegeneration and neuroinflammation – a paucity exists in 
literature on the exact site and/or mechanism of central DHEA biosynthesis. It is first 
necessary to elucidate the potential mechanisms of neurosteroidogenesis before we can 
exploit central DHEA availability for therapeutic benefit. 
2.15. Hypothesis 
In the context of chronic disease, astrocytes may play a neuroprotective role via DHEA 
biosynthesis or metabolism. We hypothesise that astrocytes are the main central site of 
intracrine DHEA biosynthesis and/or metabolism. 
2.16. Aims 
Given the known limitations of earlier techniques employed to study DHEA-related 
steroidogenesis, we aimed to elucidate biosynthesis and/or metabolism of DHEA in astrocytes 
using modern, accurate and sensitive methodology. 
A second aim was to elucidate potential species differences in this context. 
2.17. Objectives 
The following specific objectives were formulated: 
I. Investigate the ability of primary human astrocytes and rodent mixed brain culture to 
produce DHEA when supplied with appropriate substrate 
II. Investigate the ability of primary human astrocytes and rodent mixed brain culture to 






3. Materials and Methods 
3.1. Materials 
Primary cortical human astrocytes (cat # 1800) were purchased from Sciencell Research 
Laboratories (Carlsbad, CA, USA). High-glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM), gamma-irradiated Foetal Bovine Serum (FBS), Penicillin-Streptomycin (100X), 
Hanks Balanced Salt Solution (HBSS), 10x Phosphate Buffered Saline (PBS), Alexa Fluor® 
488 donkey anti-mouse secondary antibody, Alexa Fluor® 594 donkey anti-rabbit  secondary 
antibody and 0.25% Trypsin-EDTA solution were purchased from ThermoFisher Scientific 
(Glasgow, UK).  Cell culture plasticware (T75 and 6-chamber dishes) was purchased from 
Nest® (Jiangsu, China). Mouse anti-Iba1 monoclonal antibody was purchased from Abcam 
(Cambridge, MA, USA). Rabbit anti-GFAP monoclonal antibody was purchased from Cell 
Signalling Technologies, Inc. (CST) (Beverly, MA, USA). Donkey serum was purchased from 
Celtic Diagnostics (Cape Town, ZA). 
Acetic acid, sodium acetate, forskolin (from C. forskohlii), type H-1 sulphatase enzyme (from 
H. pomatia), Trilostane, Dimethyl Sulfoxide (DMSO), Methyl-tert-Butyl-Ether (MTBE), 
Methanol (MeOH), formic acid, Nunc® 8-chamber glass slides, Poly-L-lysine (PLL) and 
steroids (Pregnenolone (P5), Dehydroepiandrosterone (DHEA), androstenedione (A4), 
testosterone (T), androstanedione (5a-dione), androstanediol (3a-Adiol), androsterone (AST), 
dihydrotestosterone (DHT), progesterone (P4), 17-hydroxyprogesterone (17OHP4), 5α-
pregnan-17α-ol-3,20-dione (Pdione) were purchased from Sigma-Aldrich (now incorporated 
into Merck)(St. Louis, MO, USA). Dihydroprogesterone (DHP4), 5α-pregnan-3α,17α-diol-20-
one (Pdiol), epi-allopregnanolone (ALLO), androstenediol (A5), 17-hydroxypregnenolone 
(17OHP5) and pregnanetriol were purchased from Steraloids (Wilton, USA). 16-
hydroxyprogesterone (16OHP4) was purchased from BDH Chemical Ltd (Poole, England, 
UK). Deuterated steroid reference standards were purchased from Cambridge isotopes 
(Andover, MA, USA), these include; D2-testosterone (1, 2-D2, 98%) (D2-T), D9-progesterone 
(2, 2, 4, 6, 6 , 17A, 21, 21-D9, 98%) (D9-P4), D8-17-hydroxyprogesterone (2, 2, 4, 6, 6, 21, 
21-D8, 98%) (D8-17OHP4), D7-androstenedione (D7-A4), D6-dihydroprogesterone (D6-
DHP4), D2-androsterone (D2-AST), D4-dihydrotestosterone (D4-DHT), D6-
dehydroepiandrosterone (D6-DHEA) and D3-androstanediol (D3-3a-Adiol).FOODFRESH 
CO2 was purchased from Afrox (Cape Town, ZA). The ACQUITY UPC2® Viridis ethylene-
bridged hybrid (BEH) 2-ethylpyridine (2-EP) column (3mm×100 mm, 1.7 μm) was purchased 




3.2.1. Primary human astrocyte (pHA) cultures 
Primary human astrocytes (pHAs) were grown and maintained in high-glucose DMEM (25 mM 
D-glucose, 1 mM sodium pyruvate, 4mM L-glutamine) supplemented with 10% (v/v) FBS and 
1% (v/v) Penicillin-Streptomycin (PenStrep) (10,000 U/mL and 10 mg/mL), in a humidified 
incubator at 37°C under 5% CO2 atmosphere. 
3.2.2. Primary rat brain ex vivo mixed cell cultures (pRBMCs) 
3.2.2.1. Animals: ethical considerations 
For the rodent mixed brain cultures, brain tissue had to be harvested from young, weaned 
male Wistar rats.  Ethical exemption for tissue collection was granted by the Animal Research 
Ethics Committee of Stellenbosch University (ACU-2019-11454), on the grounds that tissue 
was harvested from animals that were culled as part of the normal husbandry procedures in 
the small experimental animal unit. The animals were maintained in a South African Veterinary 
Council (SAVC) approved facility under strict standard laboratory conditions in 12:12 light-dark 
cycle. Animals were fed standard rat chow and water was provided ad libitum. 
3.2.2.2. Tissue isolation and culture technique 
The animals were first anaesthetised with halothane gas and subsequently euthanised 
through CO2 asphyxiation. Whole brains were rapidly excised and placed in 15 mL ice cold 1X 
HBSS supplemented with 1% (v/v) Penicillin-Streptomycin. Cerebellums were removed and 
the cerebral and midbrain tissue minced with a scalpel, after which they were placed in 5 mL 
warm (37°C) 1X HBSS supplemented with 0.25% trypsin. The tissue was left to digest in a 
shaking incubator at 37°C for 30 minutes, with agitation every 10 minutes. After digestion the 
tissue suspensions were centrifuged for 5 minutes at 300 xg. The supernatants were aspirated 
and discarded, and the pellets were resuspended and triturated in high-glucose DMEM 
supplemented with 10% (v/v) FBS and 1% PenStrep (v/v). The tissue suspension was then 
placed through 70 µm cell strainer to generate a single cell suspension. The strained cell 
suspensions were then seeded into 12-well culture dishes previously coated with poly-L-lysine 
(50 µg/mL) for 1 hour at 37°C. The cell suspensions were left to grow in a humidified incubator 
at 37°C under 5% CO2 atmosphere. The culture media was refreshed 2 days after the initial 




3.2.2.3. Characterisation of primary brain cell culture  
Scanning laser confocal microscopy was utilised to visually confirm the presence of glial cells, 
particularly astrocytes, in isolated rat brain cell cultures (pRBMCs). 
Sample preparation:  
Described similarly as before, after extractions, cell suspensions were seeded on Nunc® 8-
chamber glass slides previously coated with poly-L-lysine (50 µg/mL). Once cell monolayers 
reached 80% confluency, they were fixed in 4% paraformaldehyde in PBS for 20 min at room 
temperature. Cells were then washed 3x for 5 min each in 1X PBS, permeabilised with 0.1% 
Triton-X in 1x PBS for 2 min, then subsequently washed again 3x for 5 min with 1x PBS. Cells 
were then blocked in 5% donkey serum in 1x PBS for 60 min at room temperature. After 
blocking, cells were incubated overnight with primary mouse anti-Iba1 (1:100) and rabbit anti-
GFAP (1:200) antibodies in 1x PBS containing 5% donkey serum. The following day, cells 
were again washed 3x 5 min after which they were incubated in 1x PBS containing Alexa 
Fluor® 488-conjugated donkey anti-mouse (1:200) and Alexa Fluor® 594-conjugated donkey 
anti-rabbit (1:200) antibodies for 60 min. After 60 min a Hoechst 33342 dye was added to the 
cells and left to incubate for a further 10 min. Cells were then washed 3x 5 min and then 
immersed in ≈50 µL of Dako® Fluorescent mounting medium and then frozen at -20 °C until 
imaging. 
Confocal Microscopy 
Confocal microscopy was performed on a Zeiss LSM 780 system (Carl Zeiss Microimaging, 
Germany). Data were collected by acquiring z-stacks, each with 8-12 image frames, and 
increments of ≈2 μm step width. An LCI Plan-Apochromat 63x/1.4 Oil DIC M27 objective 
equipped with a Diode 405nm CW/PS (pulsed), 488 nm laser, 561 nm laser and GaAsP 
detector (32+2 PMT), was utilised. Maximum intensity projections of z-stacks were processed 






3.2.3. Intervention treatments 
Once primary human astrocyte cell cultures reached ≈80% confluence, they were seeded into 
12-well dishes at a density of 1x105 cells per well with 2 mL of complete culture medium. Cells 
were allowed to grow for 24 hours after which the media was replaced with experimental 
culture medium.  
In the case of the ex vivo mixed rat brain cell culture, cells were seeded directly into PLL 
coated 12-well dishes, as previously described. Once the cells reached a density of ≈80% 
confluence, the steroidogenic stimulation experiment proceeded. 
Experimental medium was defined as high-glucose DMEM, as previously described, but with 
a significantly reduced serum content (0.1%). Serum was reduced, due to the presence of 
endogenous steroids in FBS, which would have been a potential confounding factor. 
The EM was then divided into 8 groups supplemented with different treatments to stimulate or 
inhibit parts of the steroidogenesis pathway, the groups are described as follows:  a basal 
(control) condition containing no treatment; Forskolin (10 µM); Pregnenolone (1 µM); Forskolin 
(10 µM) and Pregnenolone (1 µM); Forskolin (10 µM), Pregnenolone (1 µM) and Trilostane 
(10 µM); DHEA (1 µM); and lastly Forskolin (10 µM), Pregnenolone (1 µM) and DHEA (1 µM) 
(See Table 3-1). 
The rationale for these treatments is as follows: Forskolin stimulates steroidogenesis by 
upregulating adenylate cyclase activity, thereby increasing intracellular cyclic adenosine 
monophosphate (cAMP) – a secondary messenger known to stimulate steroidogenic enzyme 
activity (Seamon et al., 1981; Moriwaki et al., 1982). Forskolin was used to assess 
steroidogenic capacity in the presence or absence of P5 as well as DHEA.  
Trilostane is a known inhibitor of 3β-HSD, an enzyme critical in the conversion of P4, 17OHP4, 
A4 and T to P5, 17OHP5, DHEA and A5 respectively (Komanicky et al., 1978). Trilostane was 
used in order to distinguish whether or not the potentially produced DHEA may have been 
metabolised before it could reach detectable levels in our method. 
Cells were stimulated under these various conditions for 48 hours, after which 0.5 mL of media 




Table 3-1: Different experimental groups containing different stimulants and inhibitors of 
steroidogenesis 
 1 2 3 4 5 6 7 8 
 B F P FP FPT D FD FDT 
Forskolin (10 µM)  X  X X  X X 
Pregnenolone (1 µM)   X X X    
Trilostane (10 µM)     X   X 
DHEA (10 µM)      X X X 
 
3.2.4. Steroid Extraction  
Steroids were extracted from cell culture media using a liquid-liquid extraction technique 
utilising MTBE as a solvent. Briefly, 50 µL of deuterated reference standard mix were added 
to 0.5 mL of cell culture media in a 10 mL borosilicate screw cap vial, after which 3 mL of 
MTBE were added. Samples were then placed on an automated vortexer (SI-600, MRC Lab, 
Beijing, China) for 15 min at 1300 RPM to allow phases to interact. Once samples completed 
the shaking cycle, they were placed in the -80 °C freezer for 20 min. At this temperature, the 
aqueous phase separates, settles and freezes at the bottom of the vial while the organic 
phase, that now contains the extracted steroids, remains unfrozen on top of the aqueous 
phase. The organic phase was then decanted into a clean borosilicate glass vial and dried 
under N2 gas at 40 °C. Steroid residues were then resuspended in 150 µL of 50% HPLC-grade 
MeOH after which they were decanted into LCMS vials for analysis on the UPC2-MSMS. 
 
Table 3-2: Master mix of deuterated internal standards. Each 50 µL of the master mix contained the 
amount of respective standard below (ng): 
 
  












3.2.5. Deconjugation assay 
Conjugated steroids such as DHEAS, P5S and DHT glucuronide (DHTG) are not extracted in 
the MTBE liquid-liquid extraction technique due to the polarity of the molecules and the non-
polar nature of MTBE. One way in which to extract conjugated steroids is by enzymatically 
deconjugating an equal volume of sample and calculating the conjugated steroid content by 
the difference between the untreated and the enzyme treated samples.  
A commercially available sulphatase enzyme (STS) from the gastric juices of H. pomatia 
(Wittstock et al., 2000)  was used to deconjugate potentially sulphated steroids in samples. 
This extract also possesses potent glucoronidase activity and therefore also deconjugates 
steroids such as DHTG.  
The assay is described briefly as follows; 66 units of sulfatase (≈20 µL of 2 mg/mL in ddH2O) 
was added to each 500 µL of sample. The pH of the sample was lowered to ≈ pH 5 (the optima 
for the sulphatase enzyme) by the addition of a sodium acetate buffer – to a final concentration 
of ± 200mM (≈110 µL of buffer). Samples were then incubated for 3 hours at 55 °C in a shaking 
incubator. Samples were then removed from the incubator to cool, internal standards were 
then added and steroids were extracted as previously described. 
For every assay performed, positive controls were also deconjugated concurrently to calculate 
assay efficiency for both sulphatase and glucoronidase enzymes. Positive controls included 
were 1 µM of DHEA, DHEAS, DHT and DHTG that were extracted with or without treatment 




3.2.6. Ultra-Performance Convergence Chromatography (UPC2) – tandem 
mass spectrometry  
Steroids were separated and quantified on the ACQUITY UPC2-MS/MS (Waters, Milford, 
USA) utilising an ACQUITY UPC2 Viridis BEH 2-EP column operating in multiple reaction 
monitoring (MRM) mode (settings can be seen in table 3-3) using a positive electrospray 
ionisation (ESI+) mode. Sample injection volume was 2 µL with a method run time of 6 
minutes. The validation for this method forms part of a different PhD dissertation (Ms Desmare 
van Rooyen) and thus is not presented here for examination. 
All steroid quantifications were referenced to a standard range (0.0001–2 ng/μL) prepared in 
experimental culture media and extracted as previously described. Individual steroid 
quantifications were also referenced to a deuterated internal standard to normalise any 
potential errors in sample preparation (See Table 3-3). Internal standards that eluted closest 
RT of a given steroid analyte were selected for referenced quantification. Data were collected 
and analysed in Waters Masslynx 4.1 (Waters®). 
Limits of detection (LOD) and limits of quantification (LOQ) for each analyte are indicated in 
Table 3-4. LODs were defined as the lowest concentration detectable with a signal-to-noise 
ratio (S/N) of >3 for the quantifier ion. LOQs were defined as the lowest concentration 




Table 3-3: List of steroid standards with retention times (RT); molecular ion species and MRM mass transitions; and reference internal standards 
Steroid RT (min) Mass Transitions Reference Internal Standard 
  Quantifier Qualifier 1 Qualifier 2  
5aDione 1.39 289.20 > 253.10 289.20 > 271.20 289.20 > 97.20 D6-DHP4 
DHP4 1.42 317.00 > 95.00 317.00 > 105.20 317.00 > 175.20 D6-DHP4 
P4 1.85 315.20 > 79.15 315.20 > 123.04 315.20 > 297.00 D9-P4 
A4 1.88 287.20 > 123.00 287.20 > 173.00 287.20 > 211.10 D7-A4 or D9-P4 
AST 2.89 273.20 > 185.10 273.00 > 55.14 273.00 > 69.07 D2-AST 
Pdione 2.97 333.40 > 137.26 333.40 > 288.76 333.40 > 70.82 D2-AST 
DHT 3.08 291.00 > 255.29 291.00 > 159.00 291.00 > 104.90 D4-DHT or D2-AST 
DHEA 3.32 271.20 > 253.20 271.20 > 91.05 271.20 > 213.00 D6-DHEA 
ALLO 3.38 319.00 > 189.20 319.00 > 80.90 319.00 > 283.15 D6-DHEA 
P5 3.46 317.24 > 80.97 317.24 > 131.00 317.24 > 158.90 D6-DHEA 
17OHP4 3.65 331.10 > 122.90 331.10 > 312.80 331.10 > 295.00 D8-17OHP4 
T 3.71 289.20 > 123.00 289.20 > 186.80 289.20 > 271.18 D2-T 
16OHP4 3.94 331.20 > 97.01 331.20 > 109.10 331.20 > 313.10 D8-17OHP4 
3αAdiol 4.13 275.20 > 257.25 275.20 > 81.10 275.20 > 175.00 D3-3αAdiol 
Pdiol 4.18 317.40 > 111.00 317.40 > 299.00 317.40 > 93.15 D3-3αAdiol 
A5 4.27 273.09 > 201.17 273.00 > 129.14 273.00 > 185.28 D3-3αAdiol 
17OHP5 4.32 297.20 > 159.12 297.20 > 133.10 297.20 > 147.30 D3-3αAdiol 
Pregnanetriol 4.42 301.20 > 283.20 301.20 > 135.01 301.20 > 187.00 D3-3αAdiol 
D6-DHP4 1.42 323.17 > 85.00 323.17 > 287.07 323.17 > 305.00  
D9-P4 1.85 324.20 > 107.15 324.20 > 134.95 324.20 > 194.24  
D7-A4 1.88 294.30 > 234.00 294.30 > 118.90 294.30 > 121.15  
D2-AST 3.82 275.20 > 67.00 275.20 > 54.95 275.20 > 215.10  
D4-AST 3.04 295.20 > 105.05 295.20 > 163.19 295.20 > 215.30  
D6-DHEA 3.31 277.30 > 219.20 277.30 > 97.20 277.30 > 202.10  
D8-17OHP4 3.65 340.10 > 322.00 340.10 > 147.20 340.10 > 168.20  
D2-T 3.72 291.00 > 201.30 291.00 > 105.19 291.00 > 164.84  
D3-3αAdiol 4.15 260.20 > 178.10 260.20 > 109.10 260.20 > 135.10  
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Table 3-4: Limits of Detection (LOD) and Limits of Quantifications (LOQ) for different steroid analytes 
 
   Q – S/N  > 3 Q – S/N > 10; 1° > 3 
Range 
  Hormone LOD (ng/µL) LOD (µM) LOQ (ng/µL) LOQ (µM) 
1 5αdione 0,001 0,003 0,001 0,003 0,001-2 
2 DHP4 0,002 0,006 0,002 0,006 0,002-2 
3 PROG 0,001 0,003 0,001 0,003 0,001-2 
4 A4 0,001 0,003 0,001 0,003 0,001-2 
5 AST 0,020 0,069 0,020 0,069 0,020-1 
6 PDIONE 0,020 0,060 0,020 0,060 0,020-1 
7 DHT 0,001 0,003 0,001 0,003 0,001-2 
8 DHEA 0,010 0,032 0,010 0,035 0,010-2 
9 ALLO 0,002 0,006 0,002 0,006 0,002-0,2 
10 PREG 0,010 0,032 0,010 0,032 0,010-0,2 
11 17OHP4 0,001 0,003 0,010 0,032 0,001-2 
12 T 0,001 0,003 0,001 0,003 0,002-0,2 
13 16OHPROG 0,0002 0,0006 0,0001 0,0003 0,0002-0,2 
14 3αAdiol 0,010 0,032 0,010 0,032 0,01-0,2 
15 PDIOL 0,010 0,032 0,010 0,032 0,01-2 
16 A5 0,010 0,032 0,010 0,034 0,01-2 
17 17OHP5 0,010 0,032 0,010 0,032 0,01-2 
18 Ptriol 0,020 0,064 0,020 0,064 0,0-2 
Q – Quantifier Ion; 1° – Qualifier Ion; S/N – Signal-to-noise ratio 
LOD – Limit of detection; LOQ – Limit of quantification 
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3.2.7. Statistical Analysis 
Statistical analysis of data was performed in GraphPad Prism® 5. Data were tested for 
normalcy of distribution after which the appropriate statistical test were applied. These 
included one-way ANOVA, two-way ANOVA, as well unpaired student-t tests. For normally 
distributed data, the Bonferroni post hoc test was employed, while Dunn’s test was used for 




4. Results  
4.1. Steroidogenesis characterisation of primary human astrocytes 
Despite the use of high sensitivity methods, no steroids were detected in cell culture media 
from cells under basal conditions, nor from cells treated with 10 µM forskolin in the absence 
of P5 and/or trilostane, and DHEA.  
P5 was detectable only in treatment conditions containing ≈1µM P5 as a substrate; namely 
groups P (Fig. 4-1A), FP (Fig. 4-1B) and FPT (Fig. 4-1C). P5 concentrations were detected 
independent of forskolin and/or trilostane treatment.  
DHEA and A5 were detectable only in groups that received ≈1 µM DHEA as a substrate; 
































Figure 4-1: Detectable steroids produced by pHAs in experimental conditions containing P5 as a 
substrate with or without steroidogenic modulators: (A) P – 1 µM P5; (B) FP – 10 µM Forskolin & 1 µM 
P5; (C) FPT – 10 µM Forskolin, 1 µM P5 & 10 µM Trilostane. T0 P5 indicates initial P5 concentration of 
treatment. Data are presented as absolute steroid concentrations in µM (mean ± SD). N=3 independent 




























































































































































































































































Figure 4-2 Detectable steroids produced by pHAs in experimental conditions containing DHEA as a 
substrate with or without steroidogenic modulators: (A) D – 1 µM DHEA; (B) FD – 10 µM Forskolin & 1 
µM DHEA; (C) FDT – 10 µM Forskolin, 1 µM DHEA & 10 µM Trilostane. T0 DHEA indicates initial DHEA 
concentration of treatment. Data are presented as absolute steroid concentrations in µM (mean ± SD). N=3 










































































































































































































































4.1.1. Summary of substrate metabolism and analytes produced by pHAs 
Taken together, these results suggest that primary human astrocytes in isolation are able to 
convert DHEA into A5 (Figs 4-2A, B and C) 
Initial P5 concentrations were significantly reduced when compared to P5 recovered in groups 









Figure 4-3: Comparison between initial P5 concentration and recovered concentration after treatment 
of pHAs. P – 1 µM P5; FP – 10 µM Forskolin & 1 µM P5; FPT – 10 µM Forskolin, 1 µM P5 & 10 µM Trilostane. 
Data are presented as absolute steroid concentrations in µM (mean ± SD). N=3 independent experiments in 




















A significant reduction in DHEA concentration was observed when compared to the initial 
concentration in groups D and FD. Although a decrease was too observed in group FDT, it 
was not significant (Fig. 4-4A). 
A5 was synthesised in groups D, FD and FDT. A5 concentrations in group FD was significantly 














































Figure 4-4: Comparison between initial DHEA concentration and recovered concentration after 
treatment of pHAs (A); A5 concentrations in different conditions (B). D – 1 µM DHEA; FD – 10 µM 
Forskolin & 1 µM DHEA; FDT – 10 µM Forskolin, 1 µM DHEA & 10 µM Trilostane. Data are presented as 







4.2. Light microscopy morphological characterisation of primary rat brain ex 
vivo mixed cell culture 
After 7 days of plating primary rat brain ex vivo mixed cell culture, two distinct cell populations 
with different morphologies were observed (Fig. 4-5). The first (indicated by white arrows) had 
an elongated epithelial cell-like morphology and appeared to grow in aggregated colonies. 
The second cell population (indicated by green arrows) had distinctly small cell bodies, were 











Figure 4-5: Light micrograph of primary rat brain ex vivo mixed cell culture after 7 days of culture. 10x 
magnification. White arrows indicate cell population with epithelial like morphology. Green arrows indicate cell 
population with small cell bodies lacking processes.  
Stellenbosch University https://scholar.sun.ac.za
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4.3. Confocal analysis of primary rat brain ex vivo mixed cell culture 
confirmed the presence of astrocytes and microglia 
Confocal microscopy analysis revealed a mixed population containing both cells that were 
positive for the astrocyte (GFAP) marker and cells positive for the microglial (Iba-1) marker 
(Figure 4-6). Microglia appeared to occur in a larger proportion to astrocytes and also 
appeared to grow on top or at least in close proximity of the astrocytes. This is deduced due 
the nature in which data is acquired in the z-plane of the microscope. Like a light microscope, 
the objective (and therefore laser source) is inverted, so the detectors resolve the fluorescent 
pixels from closest to furthest from the objective. 
Two populations of Iba-1 positive cells with distinctly different morphologies were observed. 
One population was characterised as relatively smaller cells with diffuse Iba-1 staining, while 
the other consisted of larger cells with Iba-1 expression (green fluorescent signal) that formed 
structural patterns appearing cytoskeletal in nature (white arrows). These cells also seemed 












Figure 4-6: Confocal analysis of primary rat brain ex vivo mixed cell culture. GFAP (Red) labelled astrocytes and Iba-1 (green) 
labelled microglia in mixed cell population.  Hoechst nuclei stain is seen in blue. 60x magnification with 2x2 tile scan (1024x1024 





4.4. Steroidogenesis characterisation of primary rat brain ex vivo mixed cell 
cultures 
Similar to pHA samples, no steroid analytes were detected in culture media from cells under 
basal conditions nor by cells stimulated by 10 µM forskolin in the absence of P5, DHEA or 
trilostane (data not shown). 
P5 was detected groups P (Fig. 4-7A), FP (Fig. 4-7B) and FPT (Fig. 4-7C). DHEA and A5 
were detectable only in groups that received 1 µM DHEA as a substrate; namely groups D 
(Fig. 4-8A), FD (Fig. 4-8B) and FDT (Fig. 4-8C). 
























































































































































































































































Figure 4-7: Detectable steroids produced by pRBMCs in experimental conditions containing P5 as a 
substrate with or without steroidogenic modulators: (A) P – 1 µM P5; (B) FP – 10 µM Forskolin & 1 µM 
P5; (C) FPT – 10 µM Forskolin, 1 µM P5 & 10 µM Trilostane. T0 P5 indicates initial P5 concentration of 
treatment. Data are presented as absolute steroid concentrations in µM (mean ± SD). N=3 independent 



































































































































































































































































Figure 4-8 Detectable steroids produced by pRBMCs in experimental conditions containing DHEA as a 
substrate with or without steroidogenic modulators: (A) D – 1 µM DHEA; (B) FD – 10 µM Forskolin & 1 
µM DHEA; (C) FDT – 10 µM Forskolin, 1 µM DHEA & 10 µM Trilostane. T0 DHEA indicates initial DHEA 
concentration of treatment. Data are presented as absolute steroid concentrations in µM (mean ± SD). N=3 






4.4.1. Summary of substrate metabolism and analytes produced by pRBMCs 
Concentrations of P5 decreased significantly when compared to initial (T0) concentration of 


































Figure 4-9: Comparison between initial P5 concentration and recovered concentration after treatment 
of pRBMCs. P – 1 µM P5; FP – 10 µM Forskolin & 1 µM P5; FPT – 10 µM Forskolin, 1 µM P5 & 10 µM 
Trilostane. Data are presented as absolute steroid concentrations in µM (mean ± SD). N=3 independent 






Concentrations of DHEA decreased significantly when compared to initial concentration in 
treatment groups D, FD and FDT (Fig. 4-10A).  
A5 was synthesised in groups D, FD and FDT. A5 concentrations were significantly higher in 























































Figure 4-10: Comparison between initial DHEA concentration and recovered concentration after 
treatment of pHAs (A); A4 concentrations in different conditions (B). D – 1 µM DHEA; (B) FD – 10 µM 
Forskolin & 1 µM DHEA; (C) FDT – 10 µM Forskolin, 1 µM DHEA & 10 µM Trilostane. Data are presented as 









4.5. Comparison of synthesised analyte concentrations between pHAs and 
pRBMCs (species differences) 
A5 concentrations were significantly higher in pHAs compared to pRBMCs in group D. 
Concentrations remained the same between cell populations in group FD but were significantly 




















Figure 4-11: Comparison between pHA and pRBMC synthesised A5 concentrations of different 
treatment groups. D – 1 µM DHEA; FD – 10 µM Forskolin & 1 µM DHEA; FDT – 10 µM Forskolin, 1 µM DHEA 
& 10 µM Trilostane. Data are presented as absolute steroid concentrations in µM (mean ± SD). N=3 





4.6. Deconjugation assay 
4.6.1. Efficiency of sulphatase and glucoronidase enzymes 
As detailed in the methods description, conjugated steroids such as DHEAS and DHTG are 
capable of being extracted by MTBE due to their polar nature. To quantify conjugated steroids, 
samples were treated with a commercial sulphatase (STS) preparation and compared to an 
untreated (enzyme) counterpart to calculate the fraction that may exist as a conjugated steroid. 
Significantly less DHEA was detected in STS treated 1 µM DHEAS positive control when 
compared to the 1 µM DHEA positive control (Fig. 4-12A). This is calculated as desulphatasion 
efficiency of ≈48%. 
No significant difference in DHT concentration was observed when comparing 1 µM DHT to 











































Figure 4-12: Efficiency of sulphatase (A) and glucoronidase (B) enzymatic activity. DHT – 
Dihydrotestosterone; DHTG (STS) – Sulphatase treated DHTG.  Data are presented as absolute steroid 





4.6.2. Commercial sulphatase enzyme from H. pomatia demonstrates 
endogenous 3β-HSD activity 
A4 was detected in STS treated positive controls for both 1 µM DHEA and DHEAS. However, 
significantly less A4 was present in the DHEAS STS-treated vs DHEA STS-treated samples 
(Fig. 4-13).  
This data suggests endogenous 3β-HSD activity in the commercially available enzyme. The 
presence of this enzyme activity is a confounding variable as some analytes detected in non-
STS-treated samples are substrates of 3β-HSD. The implications of the presence of this 














Figure 4-13: Biosynthesis of A4 in STS treated DHEA and DHEAS positive controls. Data are presented 
as absolute steroid concentrations in µM (mean ± SD). N=3 independent experiments in triplicate. 
***(p<0.0001) 

















4.7. Detectable steroids in sulphatase enzyme treated pHA and pRBMC 
samples   
Steroid analytes detected in STS treated samples from both pRBMCs and pHAs were identical 
to untreated samples (i.e. samples not treated with STS).  
Comparisons of all detected analytes in both pHA and pRBMC STS-treated samples are 









4.7.1. Effect of STS enzyme on concentrations of P5 and P4 in pHA samples 
Significantly less P5 was present in STS-treated samples when compared to non-STS-treated 
samples in groups P, FP and FPT (Fig. 4-14A). 
P4 was detected in STS-treated samples when compared to non-STS-treated samples in 






















Figure 4-14: Comparison between P5 (A) and P4 (B) concentrations of samples from pHAs before and 
after treatment with STS in different treatment groups. P – 1 µM P5; FP – 10 µM Forskolin & 1 µM P5; 
FPT – 10 µM Forskolin, 1 µM P5 & 10 µM Trilostane. Data are presented as absolute steroid concentrations 






































4.7.2. Effect of STS enzyme on concentrations of DHEA, A4 and A5 in pHA 
samples 
DHEA concentrations remained relatively unchanged in both STS-treated and non-STS-
treated samples in groups D, FD and FDT. Although a slight decrease was noted in each 
group, albeit non-significant (Fig. 4-15A). 
A4 were detected in STS-treated compared to non-STS-treated samples in groups D, FD and 
FDT (Fig. 4-15B). 
A5 concentrations were significantly decreased in STS-treated compared to non-STS-treated 
samples in group D. A decrease was noted in STS-treated vs non-STS-treated samples in 



































Figure 4-15: Comparison between DHEA (A), A4 (B) and A5 (C) concentrations of samples from pHAs 
before and after treatment with STS in different treatment groups. D – 1 µM DHEA; FD – 10 µM Forskolin 
& 1 µM DHEA; FDT – 10 µM Forskolin, 1 µM DHEA & 10 µM Trilostane. Data are presented as absolute 
steroid concentrations in µM (mean ± SD). N=3 independent experiments in triplicate. *(p<0.05); **(p<0.0001). 

























































4.7.3. Effect of STS enzyme on concentrations of P5 and P4 in pRBMC 
samples 
P5 concentrations remained relatively unchanged in both STS-treated and non-STS-treated 
samples in groups P, FP and FPT. Although a slight decrease was noted in group P and FP, 
albeit non-significant. Surprisingly a slight increase was noted in group FPT (Fig. 4-16A). 
P4 was detected in STS-treated samples when compared to non-STS-treated samples in 
groups P, FP and FPT (Fig. 4-16B). However, P4 was likely present due to the exogenous 3β-

















Figure 4-16: Comparison between P4 (A) and P4 (B) concentrations of samples from pRBMCs before 
and after treatment with STS in different treatment groups. P – 1 µM P5; FP – 10 µM Forskolin & 1 µM 
P5; FPT – 10 µM Forskolin, 1 µM P5 & 10 µM Trilostane. Data are presented as absolute steroid concentrations 





































4.7.4. Effect of sulphatase enzyme on concentrations of DHEA, A4 and A5 in 
pRBMC samples 
DHEA concentrations remained relatively unchanged between STS-treated and non-STS-
treated samples in groups D and FDT – with non-significant decreases noted. However, a 
significant increase was observed in group FD (Fig. 4-17A). 
A4 was detected in STS-treated compared to non-STS-treated samples in groups D, FD and 
FDT (Fig. 4-17B). 
A5 concentrations were significantly decreased in STS-treated compared to non-STS-treated 
samples in group FD and FDT. A decrease was noted in STS-treated vs non-STS-treated 



































Figure 4-17: Comparison between DHEA (A), A4 (B) and A5 (C) concentrations of samples from 
pRBMCs before and after treatment with STS in different treatment groups. D – 1 µM DHEA; FD – 10 
µM Forskolin & 1 µM DHEA; FDT – 10 µM Forskolin, 1 µM DHEA & 10 µM Trilostane. Data are presented as 
absolute steroid concentrations in µM (mean ± SD). N=3 independent experiments in triplicate. *(p<0.05); 





























































5.1.  Main findings 
The topic of this thesis was to elucidate the pathways of DHEA-related neurosteroidogenesis 
in primary human astrocyte monocultures and primary rat brain mixed cell cultures, in order to 
allow an interpretation on the potential role that this neurosteroid may play in modern chronic 
disease. 
We report as main findings that, despite using the high sensitivity and specificity of UPC2-
tandem mass spectrometry, we were unable to detect de novo DHEA biosynthesis in primary 
human astrocytes and rat brain mixed glial cultures. In our opinion, this result cannot be 
ascribed to limitations in our methodology. 
Firstly, we included a condition of experimental upregulation of flux through the steroidogenic 
system. Forskolin treatment stimulates steroidogenesis by activating the adenylyl cyclase 
enzyme and raising intracellular cAMP levels (Purdy et al., 1991). P450scc is then activated 
by cAMP-dependent protein complexes (Manna et al., 2002) – thereby upregulating the rate-
limiting step in the steroid pathway (conversion of cholesterol to P5). Interestingly, one study 
has demonstrated the ability of forskolin to selectively upregulate the androgen biosynthesis 
branch of the steroidogenic pathway in the steroid hormone producing H295R human 
adrenocorticocarcinoma cell line (Cobb et al., 1996). However, the addition of forskolin could 
not bring about steroidogenesis resulting in detectable levels of DHEA either.  
Secondly, substrate utilisation was not a limitation. The inability of de novo steroidogenesis by 
astrocytes, i.e. conversion of cholesterol into P5, is a shared consensus within the available 
literature (Brown et al., 2000). At least two independent laboratories have demonstrated that 
oligodendrocytes appear to be the primary cell type involved P5 biosynthesis in the brain 
(Zwain and Yen, 1999a, 1999b; Brown et al., 2000). This supports our methodology of 
providing P5 as substrate and not cholesterol. 
Thirdly, to discount the possibility that DHEA levels were non-detectable due to its immediate 
metabolism, trilostane was used as a complimentary treatment to investigate whether DHEA 
was undergoing conversion into other androgenic metabolites in cells treated with both P5 and 
DHEA as initial substrate. Trilostane blocks 3β-HSD activity through competitive inhibition 
(Thomas et al., 2008). 3β-HSD is responsible for conversion of P5 into P4, 17OHP5 into 
17OHP4, DHEA into A4 and A5 into testosterone (T) (Figure5-1). As for other treatments, 































































Figure 5-1: The steroidogenesis pathway revisited. The red arrow indicates the mechanism in which forskolin increases the biosynthesis of pregnenolone. The green 





Finally, a particular challenge was the quantification of conjugated steroids, in particular 
DHEAS. As detailed in the materials and methods chapter, DHEAS and other conjugated 
steroids could be extracted in the same manner as their unconjugated counterparts because 
of the polar nature of their structures. A commercial sulphatase enzyme preparation (STS) 
isolated from H. pomatia was used to deconjugate potentially sulphated and glucoronidated 
steroids. Unfortunately, as our results have demonstrated, the STS preparation was not pure, 
as it exhibited exogenous 3β-HSD activity. This complicated the analysis and interpretation of 
data arising from the assay. Where relevant, analytes potentially affected by the tainted assay 
will be discussed with the cognisance of exogenous 3β-HSD activity in the assay. Interestingly, 
we are not the first to report on the artefact of 3β-HSD activity in H. pomatia STS preparations 
(Messeri et al., 1984; Wolthers et al., 1985; Christakoudi et al., 2008; Hauser et al., 2008). In 
our opinion, the presence of this artefact illustrates how even with highly advanced 
technologies such as modern chromatography and mass spectrometry, reagent quality may 
still limit the accurate quantification of conjugated steroids and our understanding of 
steroidogenesis in the brain. Nevertheless, despite the requirement to be aware of such 
limitations, we are confident that the method we employed was the best technique available 
for the purposes of the topic explored. 
Taken together, given the sensitive equipment used and the sound methodology employed, 
and our knowledge and consideration of unavoidable limitations, we are confident in our 
interpretation that current data does not support a major role for either isolated human 
astrocytes or rat mixed glial cells to synthesise significant amounts of DHEA. However, when 
considering potential DHEA metabolism, we have formulated an interpretation in line with both 
our hypothesis and current data, as well as with data previously reported in the literature 
(discussed in detail in section 5.2).  
However, of further interest, pHAs and pRBMCs were able to convert DHEA into 
androstenediol (A5), a function that was significantly enhanced by the presence of forskolin 
but unaffected by addition of trilostane. These data suggest 17β-HSD activity in both pHAs 
and pRBMCs. 
In terms of methodological inclusivity, the analytes selected to quantify were chosen based 
upon the classical steroidogenic pathway in terms of androgen biosynthesis from 
pregnenolone (P5) as well as DHEA metabolism. In addition to these, hormone analytes and 
intermediates that exist in the non-classical or so-called “backdoor pathway”(Auchus, 2004; 
du Toit et al., 2018) (Fig. 5-2) were also quantified specifically to distinguish between potential 





Given the observation that DHEA was converted into A5 in both human and animal brain cells, 
it is quite possible that the numerous beneficial effects attributed to DHEA (Kumar et al., 2008; 
Yabuki et al., 2015; Vieira-Marques et al., 2016) are possibly not a result of this steroid itself, 
but rather it’s metabolites (more on this later). 
The layout of the discussion hereon forth will primarily focus on the steroid metabolites that 
was produced at detectable levels from DHEA, by pHAs and pRBMCs, respectively. Data 
pertaining to each metabolite will be discussed in context of available literature and the 
potential physiological relevance of its biosynthesis by glial cells and its presence in human 


















































































Figure 5-2:The “hybrid” steroidogenesis pathway. Indicated in solid lines is the classical androgen branch steroidogenesis. Highlighted in pink background with 






Since the discovery of so-called neurosteroids in rodent brains by Corpéchot and colleagues 
in 1981, the process of neurosteroidogenesis has remained somewhat of an enigma in the 
literature. Although many studies have demonstrated the ability of rodent brain cells or tissue 
to synthesise steroids when provided with the relevant substrate (Hu et al., 1987; Jung-Testas 
et al., 1989a, 1989c; Akwa et al., 1991; Zwain et al., 1997; Zwain and Yen, 1999b, 1999a; 
Brown et al., 2000; Cascio et al., 2000; Gago et al., 2001; Kimoto et al., 2001; Kawato et al., 
2002; Shibuya et al., 2003; Hojo et al., 2004; Mukai et al., 2006), the data on DHEA 
biosynthesis does not appear as comprehensively characterised.  
The first study to ever mention DHEA in the rodent brain was in 1972, when it was observed 
that intracardially administered DHEA and DHEAS accumulated in trace amounts in rat brains 
(Kishimoto and Hoshi, 1972). As previously mentioned in the literature review, central DHEA 
biosynthesis was further implied due to the maintained presence of DHEAS in the brains of 
adult male rats who had undergone adrenalectomies and gonadectomies approximately two 
weeks prior to measurement (Corpéchot et al., 1981). In this study, DHEAS levels were also 
significantly higher than that of DHEA in the brain, as well as significantly higher than DHEAS 
levels in circulation (Corpéchot et al., 1981).  
Although many independent laboratories have since reported similar findings illustrating the 
presence of DHEA and DHEAS in both the human and rodent brain (Corpéchot et al., 1983; 
Robel and Baulieu, 1985; Lanthier and Patwardhan, 1986; Lacroix et al., 1987; Robel et al., 
1987; Griffiths et al., 1999; Higashi et al., 2001; Liu et al., 2003; Liere et al., 2004), very few 
have been able to actually demonstrate biosynthesis in the brain itself or by brain cells.  
To our knowledge, the first study demonstrating central DHEA biosynthesis was performed in 
isolated cells from rat neonatal cerebral cortices (Zwain and Yen, 1999a, 1999b). Utilising 
reverse transcription polymerase chain reaction (RT-PCR) and radioimmunoassay (RIA) 
techniques, the authors reported that isolated neonate cortical neurons and astrocytes 
expressed P450c17 mRNA and were able to synthesise DHEA from P5. Cortical astrocytes 
were reported to produce DHEA to a larger extent when compared to neurons, while 
hypothalamic astrocytes was reported to produce approximately 3 times more DHEA 
compared to cortical astrocytes (Zwain and Yen, 1999a, 1999b). These data were generated 
using RIA assays.  
Another study performed in isolated rat neonatal astrocytes and oligodendrocytes suggested 
that these glial cells are able to synthesise DHEA in a P450c17-independent pathway (Cascio 





were able to synthesise DHEA from P5. The addition of Fe2+ to treatment media increased the 
biosynthesis of DHEA and this enhanced effect was not affected by the P450c17 inhibitor SU 
10603. The isolated astrocytes did not express mRNA or contain P450c17 protein at all, but 
similarly were able to synthesise DHEA de novo when treated with Fe2+. The addition of 
SU10603 again had no effect on DHEA biosynthesis (Cascio et al., 2000).  
There has been only one other study investigating DHEA biosynthesis in primary human 
astrocytes and/or human brain cells – it may be of interest to note that this study was 
conducted by the same group as the previously mentioned study. In this study the authors 
assessed their hypothesised alternative Fe2+ dependent pathway in commercial normal 
human astrocytes (NHA) and human glioma cell lines (KG-1-C, MGM-1 and MGM-3). In 
addition to these cell lines, also included in the experiment, were NT2 cells, a human 
teratocarcinoma cell line, and hNT-PF cells, which are NT2 transdifferentiated neuron like cells 
with retinoic acid (Brown et al., 2000). NHA, KG-1-C, MGM-1, MGM-3, NT2 and hNT-PF all 
expressed P450c17 mRNA. KG-1-C and MGM-3 cells were able to synthesise P5 de novo 
and synthesise DHEA which was again unaffected by SU10603 (i.e. P450c17 inhibition). All 
cell lines were able to synthesise DHEA de novo, but when cells were exposed to FeSO4, 
biosynthesis was only enhanced in MGM-1, MGM-3 and NHA cells. The authors theorised 
that the P450c17 independent mechanism was due to oxidative stress and continued on to 
show that experimentally increased ROS increased DHEA production in MGM-1 cells –  effect 
ameliorated in the presence of the antioxidant Vitamin E. (Brown et al., 2003). To date, this 
laboratory and respective collaborators are the first and only that have demonstrated evidence 
for an P450c17-indpendent pathway for DHEA biosynthesis in the brain. Taken together, these 
studies seem to present a convincing body of evidence for the presence of DHEA at significant 
levels in the brain. However, in our opinion, this is highly unlikely for a number of reasons. 
Firstly, it is commonly known that the majority of DHEA in the body occurs in its sulphated 
form, DHEAS. Similarly, DHEA may be easily metabolised into a number of metabolites quite 
similar in structure to DHEA. In addition, the RIA technology employed in these fairly dated 
studies, lacked the specificity that modern UPC2-tandem mass spectrometry has. These facts 
suggest that most likely, the analytes detected and reported as DHEA in these studies, may 
have been analytes other than DHEA, but sufficiently similar in structure to DHEA, resulting in 
falsely elevated results for DHEA. Likely examples include 7α-hydroxy- and 7β-hydroxy-
DHEA, which will be discussed in detail later. These limitations preclude a firm interpretation 
on actual steroidogenic events in the brain and highlights a requirement for this to be revisited 
using modern techniques. This thesis indeed adds to this gap in the literature by confirming 






The possibility that we may not have detected DHEA because it was immediately metabolised 
into an analyte not listed in our method is a possibility that should be considered. Indeed, in 
our opinion, given the fact that in vivo, DHEA is readily converted into its closely related 
intermediates in the steroidogenic pathway such as A5, it is likely that if DHEA was produced, 
it was metabolised into other intermediates which was not specifically included in our 
assessment panel. A likely possibility is that newly synthesised DHEA may have been 
metabolised to its hydroxy metabolites 7α-hydroxy-DHEA (7α-DHEA) and 7β-hydroxy-DHEA 
(7β-DHEA). These hydroxy analytes are synthesised when DHEA is converted by the enzyme 
CYP7B1 into 7α-DHEA (Rose et al., 1997). 7α-DHEA is a ligand for 11β-HSD1, which 
interconverts it into 7β-DHEA - the same enzyme responsible for the conversion of cortisol to 
cortisone. The anti-glucocorticoid activity of DHEA has actually been proposed to be due to 
7α-DHEA and 7β-DHEA metabolites (Hennebert et al., 2007). One study has suggested that 
the accumulation of DHEA in the brains of AD patients may be due to the loss in ability to 
convert DHEA into its hydroxy metabolites (Kim et al., 2003).  
Unfortunately, at the time of the current study, specific reference standards for 7α-DHEA and 
7β-DHEA could not be sourced. Thus, given the current data showing non-detectable DHEA 
levels – in contrast with the earlier literature – it is recommended that this possibility be 
revisited as soon as appropriate reference standards are available. 
Another limitation in terms of reagents - the exogenous 3β-HSD activity in the STS H. pomatia 
preparation - precludes a firm interpretation on whether or not DHEA may have been produced 
and sulphated to DHEAS by pHA and pRBMCs. However, several indirect results may suffice 
in the argument that it is unlikely DHEA was sulphated by these cells. For example, in the 
current study, cells treated with P5 as substrate, DHEA was undetectable, but no 
androstenedione (A4) (the conversion of which would have been facilitated by STS, from 
DHEA) could be detected in the STS treated samples either. This suggests that no DHEA was 
sulphated under the conditions assessed. In addition, SULT – which catalyses the sulphating 
of DHEA and P5 into DHEAS and P5S respectively – has demonstrated low activity  in the 
rodent brain (Rajkowski et al., 1997) and its mRNA is expressed in very low to non-detectable 
levels in human brain (Steckelbroeck et al., 2004). In fact, the human brain expresses high 
levels of STS mRNA – the translation of which would result in enzyme deconjugation of 
DHEAS and P5S (Steckelbroeck et al., 2004). Furthermore, studies investigating the effect of 
systemically administered DHEA on brain DHEAS concentrations in rats demonstrated no 
significant increase in central concentrations of DHEAS (Kishimoto and Hoshi, 1972; Young 
et al., 1991). These data, albeit dated, suggest that DHEAS concentrations centrally are 





Taking this into account, the systemically independent central biosynthesis of DHEAS does 
not preclude it from existing mainly in a precursor capacity.  
Lastly, despite the aberration in the sulphatase assay, it is the opinion of the authors that pHAs 
and pRBMCs are likely not capable of synthesising DHEA in its unmetabolized form, even in 
the presence of added P5. Although trilostane was used to prevent the conversion of DHEA 
to A4 and STS used to deconjugate potentially synthesised DHEAS, these are not the only 
metabolites that DHEA may be converted into, of which the hydroxylated epimers are an 
example. 
In the sections to follow it will become evident that these cell populations/types are anything 
but devoid of steroidogenic capacity. 
5.3. Androstenediol (A5) 
Both pHAs and pRBMCs demonstrated the ability to convert DHEA into androstenediol (A5), 
which is in line with the  reports of 17β-HSD mRNA (Martel et al., 1992; Normand et al., 1995; 
Pelletier et al., 1995; Beyenburg et al., 2000; Steckelbroeck et al., 2001, 2003) in both human 
and murine astrocytes and microglia, as well as 17β-HSD protein (Pelletier et al., 1995) and 
activity (Zwain and Yen, 1999b) in murine astrocytes. To date, there has only been two reports 
of A5 presence in rodent brains (Tagawa et al., 2006; Qaiser et al., 2017). The first study 
assessed and compared the differences of neurosteroid concentration in different strains of 
mice, and reported A5 in all strains (Tagawa et al., 2006). The strains assessed included 
DBA/2, ICR, BALB/c, ddY and C57BL/6 mice. Steroid concentrations in all strains were 
compared to DBA/2 mice as the control and A5 concentrations were significantly lower in 
BALB/c and ddY mice as a result. The second study, as mentioned already in section 5.3, only 
demonstrated the ability of rat brains to convert DHEAS into A5 once it crosses the BBB 
(Qaiser et al., 2017). Murine DHEA conversion to A5 seem to be largely ascribed to microglial 
cells (Jellinck et al., 2007; Gottfried-Blackmore et al., 2008), but current data suggest a 
significant role for astrocytes as well. Furthermore, no reports exist on A5 presence in human 
brains, although the capacity to synthesise A5 and A5 sulphate from DHEA and DHEAS has 
been demonstrated in human brain tissue homogenates (Kishimoto and Hoshi, 1972; 
Kishimoto, 1973; Weill-Engerer et al., 2003). Further investigation is required to confirm 
whether human microglial cells may also contribute to A5 levels in the brain. 
The potential for A5 biosynthesis to occur in both astrocytes and microglia in pRBMC culture 
is a possibility. However, PBCRs only produced significantly more A5 in samples that were 
treated with DHEA, forskolin and trilostane. pHAs produced significantly more A5 compared 





pRBMCs compared to pHAs in all experimental conditions suggests that astrocytes may 
contribute to A5 biosynthesis to a larger extent when compared to microglia. Interestingly, A5 
concentrations were significantly increased with the addition of forskolin relative to DHEA 
alone in both pHA and pRBMC cultures. Similarly, this has been reported that forskolin also 
increases 17β-HSD activity in H295R cells (Bird et al., 1996).  
Interestingly, systemic administration of LPS in male rats also causes a significant increase in 
17β-HSD mRNA expression in brains relative to control, but interestingly, a relative decrease 
in the testis (Sadasivam et al., 2014). Similarly, LPS treatment of primary mouse microglia 
also caused a significant increase in 17β-HSD mRNA expression (Gottfried-Blackmore et al., 
2008). However, in the latter study the LPS had no significant effect on the conversion of 
DHEA into A5. The lack of the change in A5 concentrations after LPS treatment could not be 
attributed to increased conversion of A5 into testosterone, as these concentrations also 
remained unchanged. Levels of estradiol and estrone, downstream metabolites were not 
measured, but the isolated primary microglia did not express detectable levels of P450aro 
mRNA – which encodes for the enzyme responsible for the conversion of T into estradiol 
(Gottfried-Blackmore et al., 2008). Therefore, the lack in the change of A5 concentrations, 
despite an increase in 17β-HSD cannot be attributed to increased flux through the pathway. 
The data demonstrating the effects that LPS may have on 17β-HSD mRNA expression, further 
suggest that A5 has a role in limiting neuroinflammation. Indeed, A5 treatment of LPS treated 
BV2 murine microglia caused a significant reduction in IL-6 mRNA expression relative to 
control. Similarly, systemic administration of A5 in LPS treated mice caused a significant 
reduction in IL-6 mRNA expression in the substantia nigra, relative to control and improved 
clinical outcome measures in a mouse model of experimental autoimmune encephalomyelitis 
(EAS) (known to mimic multiple sclerosis pathology)(Saijo et al., 2011). Interestingly, this 
beneficial effect of A5 was abrogated in ERβ knockout mice in this study – suggesting a role 
for this receptor in A5-mediated anti-inflammatory action. Furthermore, although ERβ had a 
higher affinity for 17β-estradiol, its commonly excepted ligand, the anti-inflammatory effect 
was unique to A5 as opposed to 17β-estradiol (Saijo et al., 2011). 
Others have also reported A5 to be neuroprotective (Hanna et al., 2015), myelin promoting 
(Kalakh and Mouihate, 2015, 2017) as well as possessing anti-inflammatory properties (Ben-







5.4. Summary of findings 
This study has demonstrated that primary human astrocytes (pHAs) and primary rat brain 
mixed cell cultures (pRBMC) do not possess the ability to synthesise DHEA when provided 
with pregnenolone (P5) as a substrate (Fig. 6-1). These findings conflict with previous reports 
(Zwain and Yen, 1999a, 1999b).  
 
pHAs and pRBMCs were able to synthesise P4 from P5 as a substrate. Although P4 was 
detected in both pHA and pRBMC cultures treated with P5, it does not account for the 
significant loss of P5 after treatment in both cultures. This suggests metabolism of P5 into a 
steroid(s) that were not in our list of analytes (Fig. 6-1). The P5 may have been metabolised 
down the mineralocorticoid branch of steroidogenesis, but it is also possible that DHEA was 
hydroxylated to form 7α- and 7β-hydroxy-DHEA (Rose et al., 1997; Jellinck et al., 2001, 2007; 
Weill-Engerer et al., 2003). At the time of these experiments, we did not possess the standards 
for the hydroxylated metabolites of DHEA, but it is certainly something that needs to be 
investigated in subsequent experiments.  
Primary human astrocytes and primary rat mixed glial cells were also able to synthesise 
androstenediol (A5) from DHEA as a substrate. To the best of the authors knowledge, this is 
the first study to report the direct biosynthesis of A5 by primary human astrocytes from DHEA 
as a substrate. 
Although we did not measure 17β-HSD enzyme expression, the presence of this enzyme and 
its activity was clear due to the products of its activity being detected. Additionally, the rationale 
to measure the expression of other enzymes, such as P450c17, was also decided against 
since no products could be detected.  
Lastly, the lack of detection of some steroid analytes in the method also suggests that pHAs 
and pRBMCs are not able to biosynthesise DHT through the classical or backdoor steroid 
pathway. This too is a novel finding.  
Figure 5-3: Summary of metabolism of pregnenolone (P5) and dehydroepiandrosterone (DHEA) by 







The published studies supposedly demonstrating the first evidence of DHEA biosynthesis in 
astrocytes utilised RIA methods, which at the time were probably the best techniques for 
measuring steroid analytes. Indeed, even presently, immunoassay based techniques are still 
utilised in clinical environments because of its speed, practicality and cost (Fanelli et al., 2011). 
However, decades have passed since the publication of these seminal studies and better 
technologies such as UPC2-tandem mass spectrometry have emerged. Given the complexity 
of steroid structures and the multitude of intermediary metabolites that exist in the steroid 
pathway, it is possible that antibodies used in immunoassays cross-react with other steroids, 
especially at  low concentrations (Fanelli et al., 2011; Krasowski et al., 2014; Stokes et al., 
2014), such as is expected at sites of intracrine steroidogenesis. 
The demonstrated metabolism of exogenous DHEA provided as substrate suggests a small 
chance that DHEA potentially produced from P5 may also have been metabolised into other 
analytes not included in our analysis panel and was therefore not detected in groups treated 
with P5. However, the fact that more A5 was detectable only in groups that were provided 
exogenous DHEA, argues against this. 
It is therefore our opinion that DHEA is likely not synthesised by astrocytes. Nevertheless, 
given the importance of astrocyte function in the context of neuroinflammation, as well as the 
beneficial effects attributed to both DHEA and its metabolites, it is clear that these hormones 
have a significant role in the limitation of neuroinflammation. 
Since current data argues against central biosynthesis of DHEA, the demonstrated significant 
levels of DHEA present in the brain, can only come from the periphery. Assuming that this is 
the case, we interpret the ”central DHEA picture” as follows: Firstly, although data suggest 
that DHEA sulphation is independent of the periphery (Young et al., 1991), a more recent 
publication  reports that DHEAS does not readily cross the BBB (Qaiser et al., 2017) and that 
when it does, it is desulphated in the process (Qaiser et al., 2017). Systemic administration of 
DHEA in rats increases central DHEA concentrations, but central DHEAS concentrations 
remain  unchanged (Young et al., 1991). Furthermore, Corpéchot and colleagues showed that 
DHEA and DHEAS levels in rodent brains remained unchanged after gonadectomies and 
adrenalectomies (Corpéchot et al., 1981). Similarly, systemic steroidogenic modulators had 
no effect. However, DHEAS levels still remained higher than those of DHEA and the levels of 
both remained unchanged after 15 days – this suggested central biosynthesis to the authors. 
However, we suggest that DHEAS may exists in the brain as a long-term depot for DHEA 





sulphated once inside the brain to keep it there and that it is only desulphated at the 
appropriate time (i.e. neuroinflammation and/or damage), in order to allow it to be metabolised 
into anti-inflammatory metabolites.  
Secondly, although systemic levels of DHEA decline with age and neurodegeneration, levels 
in the central compartment are reported to be abnormally elevated in pathologies such as 
Alzheimer’s disease (AD) (Marx et al., 2006) and multiple sclerosis (MS) (Orefice et al., 2016). 
Generally, the increased levels would be ascribed to increased biosynthesis, but decreased 
metabolism of DHEA also needs to be considered, as such a decrease in the production of 
neuroprotective anti-inflammatory metabolites such as A4 and A5, could indeed increase the 
risk for neurological pathology. Indeed, others have also come to this conclusion (Yau et al., 
2003).  
Thirdly, our theory of a central DHEA depot also holds true in context of the disproportionate 
development of neurodegenerative pathologies that affect women more than men, such as 
AD (Mielke et al., 2014) and MS (Koch-Henriksen and Sørensen, 2010; Kalincik et al., 2013). 
Serum DHEA and DHEAS levels generally decrease with age in both men and women. After 
menopause, however, adrenal steroidogenesis becomes the main source of circulating 
androgens in women. When ovarian and adrenal steroid biosynthesis declines significantly or 
ceases, due to menopause and age respectively, circulating DHEAS/DHEA levels decline 
significantly as well. Provided with our theory of the importance of the DHEA metabolites in 
the brain, if no DHEA from the periphery exists as a precursor this would clearly provide the 
basis of an explanation for the importance of this hormone in regulating neuroinflammatory 
conditions. This is also an explanation as to why post-menopausal women are more likely to 
develop these pathologies compared to men. 
Taken together, it remains clear that DHEA has a significant role in the maintenance of 
homeostasis in the brain and although we cannot provide evidence for its central biosynthesis, 
we have demonstrated evidence for its metabolism. It is also clear that DHEA metabolism in 
the brain is significantly different from the periphery. 
Finally, in terms of clinical application of this knowledge, although systemic administration of 
DHEA raises central concentrations of DHEA in mice (Young et al., 1991), it is probably not a 
viable treatment in humans due to its strong androgenic properties and numerous side effects, 
such as hirsutism and acne in women (Petri et al., 2004). However, since metabolites 
downstream of DHEA in the steroidogenic pathway also exert these beneficial effects, should 
we not attempt to exploit them instead? Further studies should thus move forward by 
comprehensively characterising any other steroid analytes that may be synthesised from 





of these metabolites needs to be quantified by ascertaining whether the therapeutic usage 
may outweigh potential negative systemic side effects and whether these metabolites can 
cross the BBB after systemic administration.  
To test our DHEAS depot hypothesis we propose using a model similar to one utilised by 
Corpéchot and colleagues (1981). However, after gonadectomies and adrenalectomies, we 
propose simulating a neuroinflammatory environment through systemic administration of a 
high dose of LPS. We would then investigate potential changes in central levels of DHEA and 
DHEAS, as well as metabolite A5, in response to the LPS stimulus. If our theory proves 
correct, the DHEA and DHEAS concentrations should significantly decline, but won’t return to 
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